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The microtubule associated protein tau is a causative factor in a class of 
neurodegenerative diseases termed tauopathies.  Alzheimer’s disease (AD) is the 
most prevalent tauopathy.  In AD, natively unfolded, tau becomes 
hyperphosphorylated, and undergoes a conformational change allowing hexapeptide 
regions near microtubule binding repeat region 2 to aggregate into fibers.  Tau exists 
in neurons as six alternatively spliced isoforms.  The expression levels of tau are not 
changed in many tauopathies; however, various levels of each isoform can be 
included in aggregation depending on the disease.  This indicates post-translational 
modifications or interactions with other proteins causes certain tau isoforms to be 
included in or excluded from these insoluble inclusions.  Tau functions by assembling 
and stabilizing microtubules and is regulated by phosphorylation.  In AD, the 
phosphorylation state of tau is altered so the affinity for microtubules is reduced; 
however, how changes in tau phosphorylation affect polymerization of tau isoforms is 
not fully understood.  Abnormal aggregation of protein in a cell is mediated by 
molecular chaperones.  A class of molecular chaperones, heat shock proteins, is 
upregulated in response to cellular stress.  The most widely involved is heat shock 
protein 70 (Hsp70), which has upregulated and inversely proportional protein levels 
to tau aggregation in hippocampal neurons.  Hsp70 can increase tau solubility in cells; 
however, it is unknown if Hsp70 can act directly on tau to prevent its dysfunction.  
This dissertation explores how phosphorylation with GSK-3β, the major kinase 




affect tau dysfunction (polymerization) and function (microtubule binding and 
assembly).  Tau isoforms were found to be differentially affected by phosphorylation, 
as indicated by differences in their overall polymerization and various morphologies.  
Likewise, tau phosphorylation differentially affected their affinity for stabilized 
microtubules.  Tau isoform polymerization was inhibited by Hsp70, with various 
concentrations of Hsp70 needed for complete inhibition.  Finally, while Hsp70 altered 
the microtubule assembly properties of tau isoforms, each individual isoform was 
able to assemble microtubules robustly.  Taken together, this dissertation shows tau 
isoforms respond differently to modifications and interaction with Hsp70, indicating 











Throughout life, a select few individuals can provide the needed guidance to tackle 
the current challenges of the day.  For the past five years, Dr. Chris “Professor 
Chaos” Gamblin has provided me with this guidance.  He has always wanted a 
nickname, and what better place to give him one than an official publication.  Dr. 
Gamblin was generous enough to give me the opportunity to do a summer rotation 
during 2006, and accept me into his lab.  While I am sure I have tried his patience 
more than once a week, he has stuck with me and continues to provide advice on how 
to be a better scientist and writer.  I would definitely like to thank him for kicking me 
in the hand “accidentally” during indoor soccer in February 2011, while I was writing 
my dissertation and making it extremely difficult to type using only one good hand. 
 
Next, I would like to thank all the lab members that have come and gone through the 
years.  Shaun Carlson, an undergrad who was here during the beginning of my 
graduate career and the first author on the paper I contributed to during my rotation.  
Dr. Carolyn Rankin, whose insight and expertise was much appreciated during my 
beginning years.  On a personal note, she was a great help when I got my dog and her 
expertise in dog training aided in my becoming an owner. I would like to thank the 
excellent lab technician, Michael Branden, who taught me about protein purification 
and helped with learning techniques early on.  Dr. Qian Sun, who was the first 
graduate student in the lab, and who gave me a lot of advice dealing with graduate 




why the University of Iowa will always trump Iowa State University. I would also 
like to acknowledge the numerous undergrads that have helped with the background 
preparation work for experiments. 
 
I am most appreciative to my committee members Drs. Kelly, Lundquist, Azuma, 
Davido, and Michaelis who gave me the opportunity to continue and recommended 
me for doctoral candidacy.  Their guidance through grant writing and in completing 
my degree has been insightful.   
 
I would like to thank most of all, my parents, who I owe my life.  Without them, I 
would never have had this opportunity.  They have provided encouragement and 
advice throughout my life, and I appreciate their support every day.   
 
Finally, I would like to thank my dog, Monty, who has put up with the long hours, 
and sometimes the lack of attention as I have been writing my grant and dissertation, 
and completing my research.  He will not understand how much I wish I could hang 
out with him more, but dad has to pay the bills.  I am grateful to him for not 








Table of Contents…………………………….…………………………..….………vii 
List of Figures…………………………………………………………………..…..x 
Chapter 1 Introduction 
1.1 Tau……………………………………………………….………………………1 
 1.1.1 Overview……………………………………….………………………1 
 1.1.2 Tau is alternatively spliced……………….……………………………1 
 1.1.3 Tau is expressed mainly in neurons……………………………………2 
 1.1.4 The primary sequence of tau…………………………………………4 
 1.1.5 Tau interacts with tubulin………………………………………………4 
1.2 Amyloid….............……..…………………………………………………………7 
 1.2.1 Overview………………………………………………………………7 
 1.2.2 Formation………………………………………………………………9 
1.3 Tau Dysfunction ………………………………………………………………12 
1.4 Tauopathies………………………………………………………………………14 
 1.4.1 Overview……………………………………………………………….14 
 1.4.2 Alzheimer’s disease (AD).…………………………………………....15 
 1.4.3 Pick’s Disease (PiD)……………………….…………………………18 
 1.4.4 Progressive supranuclear palsy (PSP) and corticobasal degeneration 
 (CBD)…………………………………….………………………..…………18 
 1.4.5 Frontotemporal dementia with parkinsonism associated with
 chromosome 17 (FTDP-17)……………………………………………….…19 
1.5 Tau phosphorylation……………………………………………………………21 
1.6 Chaperones………………………..…………………………………………….24 
 1.6.1 Overview…………….………………………………………………..24 
 1.6.2 Heat Shock Protein (Hsp70)….......…………………………………25 
 1.6.3 Hsp70 Mechanism of action…………………………………………25 
 1.6.4 Hsp70 in AD…………………………………………………………26 
1.7 Overall summary and hypothesis  ………………………………………………27 
 
Chapter 2- Methods 
2.1 Tau expression and purification.............................................................................29 
2.2 Arachidonic acid (ARA) induced tau polymerization (Chapter 3 Part 1).............30 
2.3 Heparin induced tau polymerization (Chapter 3 Part 1)........................................31 
2.4 ARA induced tau polymerization (Chapter 3 Part 2).............................................31 
2.5 Heparin induced tau polymerization (Chapter 3 Part 2)........................................31 
2.6 Right angle laser light scattering (LLS).................................................................32 
2.7 Thioflavine S (ThS) Fluorescence.........................................................................32 
2.8 Transmission Electron Microscopy (TEM)...........................................................33 
2.9 ARA and heparin induced tau polymerization kinetics……………………….34 
2.10 Glycogen Synthase Kinase-3β (GSK-3β) phosphorylation of tau isoforms…34 
2.11 ARA polymerization of GSK-3β phosphorylated tau isoforms.…………….35 




2.13 Binding of unphosphorylated tau to microtubules……………………………35 
2.14 Binding of phosphorylated tau to microtubules…………………………….…37 
2.15 Hsp70 expression and purification………………………………….…………37 
2.16 ARA, Congo red (CR) or heparin induced tau polymerization with Hsp70...38 
2.17 LLS kinetics with Hsp70 and 2N4R tau……………………………………….39 
2.18 ATP involvement in Hsp70 inhibition of ARA induced 2N4R tau 
 polymerization………………………………………………………………39 
2.19 Addition of Hsp70 after 2N4R tau polymerization to determine if filaments can 
 be disassembled…………………………….………………………………40 
2.20 50% inhibition of tau polymerization values…………………………………40 
2.21 Analysis of electron microscopy images with Image Pro Plus………………..40 
2.22 Microtubule assembly assay and data fitting……….…………………………41 
 
Chapter 3- Tau Polymerization is Limited by Inducer Concentrations and GSK-
3β Phosphorylation Differentially Affects Tau Isoforms 
 
Part 1. ARA and Heparin induced 2N4R Tau Polymerization In Vitro 
3.1.1 Introduction…….………………………………………………………………42 
3.1.2 Results 
 3.1.2.1 ARA and heparin induced formation of tau filaments………………44 
 3.1.2.2 Polymerization of 2N4R tau with ARA and heparin produces a 
 biphasic dose response…………………………………………………….…45 
 3.1.2.3 2N4R polymerization kinetics with ARA………………………....…50 
 3.1.2.4 2N4R polymerization kinetics with heparin..…………………..……51 
3.1.3 Conclusions……………………………………….……………………………54 
 
Part II- GSK-3β Phosphorylation Differentially Affects Tau Isoform 
Dysfunction and Function 
3.2.1 Introduction…………………………………………………………………...56 
3.2.2 Results 
 3.2.2.1 Tau isoforms………….……………………………………………59 
 3.2.2.2 Isoform differences in ARA induced polymerization………………59 
 3.2.2.3 Isoform differences in heparin induced polymerization……………61 
 3.2.2.4 Tau isoforms are phosphorylated by GSK-3β……….………………65 
 3.2.2.5 Microtubule binding of tau isoforms changes with phosphorylation by 
 GSK-3β……………………………..………………………………………..67 
 3.2.2.6 Phosphorylation of tau isoforms changes filament polymerization 
 levels…………………………………………………………………………68 
 3.2.2.7 Phosphorylation of tau isoforms changes filament morphology…….70 
3.2.3 Discussion……………………………………………………………………...73 
 






 4.2.1 Hsp70 inhibits ARA induced 2N4R tau polymerization……………..82 
 4.2.2 Other inducers of tau polymerization………………………………...84 
 4.2.3 Hsp70 acts by slowing the elongation of 2N4R tau….……………….88 
 4.2.4 ATP does not affect Hsp70 inhibition of 2N4R tau polymerization…88 
 4.2.5 Addition of Hsp70 after filament formation slightly decreases filament 
 lengths………………………………………...…………………………….91 
 4.2.6 Hsp70 differentially inhibits other tau isoform polymerization..…….94 
 4.2.7 TEM analysis of tau isoform inhibition……………………………....98 
 4.2.8 Hsp70 affects tau associated microtubule assembly………………….102 
4.3 Discussion………………………………………………………………………105 
 
Chapter 5-Conclusions and future directions…………………………………111 
 







Figure 1.1 Tau isoforms are alternatively spliced at exons 2, 3 and 10 and known GSK-3β sites...........3 
Figure 1.2 Overview of tau phosphorylation leading to dysfunction........................................................8 
Figure 1.3 General Amyloid structure.....................................................................................................10 
Table 1.1 Summary of isoform differences between tauopathies...........................................................20 
Figure 3.1 Nonlinearity of tau polymerization with regulatory molecules.............................................46 
Figure 3.2 Variation of regulatory molecule concentrations in tau polymerization reactions................47 
Figure 3.3 Length distribution of tau filaments changes as a function of protein concentration............49 
Figure 3.4 Kinetics of ARA induction of tau polymerization.................................................................52 
Figure 3.5 Kinetics of heparin induction of tau polymerization.............................................................53 
Figure 3.6 Variation between tau  isoforms............................................................................................60 
Figure 3.7 ARA induction of tau isoform polymerization......................................................................62 
Figure 3.8 Polymerization of 0N3R and 0N4R isoforms with 75 μM ARA into larger aggregates.......63 
Figure 3.9 Heparin induction of tau isoform polymerization..................................................................64 
Figure 3.10 GSK-3β phosphorylation of tau isoforms changes gel mobility and phosphate 
 incorporation.............................................................................................................................66 
Figure 3.11 Changes in microtubule binding of tau isoforms when phosphorylated with GSK-3β.......69 
Figure 3.12 Effect of phosphorylation on tau isoform polymerization...................................................71 
Figure 3.13 TEM images of ARA induction of GSK-3β phosphorylated tau isoforms..........................72 
Figure 4.1 Hsp70 inhibition of ARA induced 2N4R tau polymerization................................................83 
Figure 4.2 Hsp70 inhibition of CR induced 2N4R tau polymerization...................................................86 
Figure 4.3 Hsp70 inhibition of heparin induced 2N4R tau polymerization............................................87 
Figure 4.4 Hsp70 inhibits tau polymerization by slowing the elongation rate........................................89 
Table 4.1 LLS kinetics of ARA induced 2N4R tau polymerization with varying Hsp70 
 concentrations...........................................................................................................................90 
Figure 4.5 The contribution of ATP to Hsp70 inhibition of tau polymerization....................................92 
Figure 4.6 Hsp70 partially disassembles tau filaments in the presence of ATP.....................................93 
Figure 4.7 Hsp70 inhibition of ARA induced tau isoform tau polymerization.......................................95 
Table 4.2 Concentration of Hsp70 required to inhibit maximum ARA induced tau isoform 
 polymerization by 50% and p-values comparing each data set................................................96 
Figure 4.8 Electron micrographs of Hsp70 inhibited tau isoform polymerization with ARA................99 
Figure 4.9 Electron micrograph filament length distributions of Hsp70 inhibited tau isoform 
 polymerization........................................................................................................................100 
Figure 4.10 0N4R aggregates artificially skew quantitation of electron microscopy data...................101 
Figure 4.11 Microtubule assembly with tau isoforms and Hsp70.........................................................103 




Figure 4.12 The global hairpin configuration of tau.............................................................................107 
Figure 5.1 Predicted hydrophobic regions of tau isoforms...................................................................125 
Table 5.1 Summary of tau isoform differences determined by this dissertation...................................126 
Figure A.1 Hsp70 and 2N4R tau bound to antibodies do not stay bound to Protein G beads..............128 
Figure A.2 SDS-PAGE of thrombin cleavage of Hsp70 to remove histidine tag.................................129 
Figure A.3 Western blot for anti-histidine tag of thrombin cleaved Hsp70..........................................130 
Figure A.4 Tau and non-his-tagged Hsp70 immunoprecipitation with magnetic nickel agarose 
 beads........................................................................................................................................131 
Figure A.5 Isothermal titration calorimetry (ITC) of Hsp70 and 2N4R tau to determine binding 
 constants (from 5-24-10).................................................................................................132-133 
Figure A.6 ITC of Hsp70 injection into buffer (from 5-25-10).....................................................134-135 
Figure A.7 ITC was run using an automated version of the VP-ITC (from 8-12-10)...................136-137 
Figure A.8 ITC of Hsp70 and 2N4R tau shows difficultly reproducing results (from 8-18-10)...138-139 
Figure A.9 Surface plasmon resonance (SPR) using the BIAcore........................................................140 
Figure A.10 A substrate binding domain (SBD) peptide for Hsp70 binds to Hsp70, but not to Tau12 
 antibody or the reference channel...........................................................................................141 
Figure A.11 2N4R tau and Hsp70 kinetic analysis...............................................................................142 
Figure A.12 SPR of 3R tau....................................................................................................................143 
Figure A.13 SPR of Δ277, 278,308,309-2N4R tau...............................................................................144 





Chapter 1 Introduction 
1.1 Tau 
1.1.1 Overview 
The microtubule associated protein tau was discovered in 1975, as a protein that 
could assemble neuronal tubulin into microtubules (1).  Tau association with 
microtubules is regulated primarily by phosphorylation of tau.  Excessive 
phosphorylation severely reduces the affinity of tau for microtubules and can induce a 
conformational change that allows tau to aggregate with itself.  This aggregation is 
seen in many diseases associated with dementia, of which Alzheimer’s disease (AD) 
is the most prevalent.  Modeling the mechanism by which tau polymerizes has proven 
difficult, as many factors such as other post-translational modifications and other 
cellular proteins such as chaperones can influence the process.  We propose that our 
in vitro system can be used to study how phosphorylation of tau and interactions of 
tau with other proteins influences the function of tau, such as microtubule assembly 
and binding, and tau dysfunction such as polymerization into filaments.  This chapter 
provides background information on the current knowledge of tau biology germane to 
the studies performed.    
 
1.1.2 Tau is alternatively spliced 
The gene for tau, MAPT, is located on chromosome 17 at position 17q21 (2) and 
contains 16 exons (3, 4).  Tau mRNA contains up to 13 exons, as exon 4A, 6, and 8 





are transcribed, but never translated (5, 7, 8).  Exons 2, 3 and 10 of tau mRNA can be 
alternatively spliced to form 6 different isoforms in human neurons (3).  Exons 2 and 
3 in the N-terminal region can take the pattern of +2+3, +2-3, or -2-3 resulting in the 
naming of 2N, 1N or 0N, respectively.  Exon 3 is only included in the presence of 
exon 2 (4).  Exon 10 encodes for the second of four functional microtubule binding 
repeat (MTBR) regions.  The absence of exon 10 results in three MTBR (3R) while 
the presence of exon 10 results in four MTBR (4R).  The alternative splicing of tau 
results in the 6 isoforms that vary in size from 352 to 441 amino acids (Figure 1.1) (7).   
 
1.1.3 Tau is expressed mainly in neurons 
The fetal form of tau, 0N3R is the only isoform expressed in neurons during 
development and up to 8 days postnatal in rats (9).  After this time all six isoforms are 
expressed (10), however not at equivalent levels.  Tau protein levels of normal human 
adult cortex indicate equal levels of 3R and 4R tau.  The differences arise when 
examining the number of N-terminal exons.  1N isoforms compose about 50%, 0N 
isoforms compose about 40% and 2N isoforms compose about 10% of cellular tau 
(11).  It is presently unknown what regional and neuron to neuron specific differences 
in tau isoform expression levels are.   Due to these differences in expression, tau 
isoforms may have specific functions as defined by their primary sequence.  This 
dissertation examines whether differences in primary sequences can lead to changes 






Figure 1.1 Tau isoforms are alternatively spliced at exons 2, 3 and 10 and known 
GSK-3β sites.  Tau exists as six alternatively spliced isoforms that differ by the 
inclusion of exons 2 (red box), 3 (blue box) in the N-terminal region and exon 10 
(green box) in the microtubule binding repeat region (repeats are colored yellow).  
Inclusion of exons 2 and 3 results in the naming 2N, inclusion of exon 2 results in the 
naming 1N, and inclusion of neither exon results in the naming 0N.  Exon 10 encodes 
for microtubule binding repeat 2, and in the absence of exon 10, only 3 microtubule 
binding repeats are present resulting in 3R, or 4R if exon 10 is included.  The number 
of amino acids in each isoform is indicated on the right side of the figure.  The 
various domains and regions are labeled in the bottom figure.  Also labeled are GSK-





1.1.4 Primary sequence 
The primary sequence of tau can be divided into two domains as defined based upon 
their proposed functions (Figure 1.1).  The projection domain is composed of two 
regions, the acidic N-terminal region of the protein, which includes exons 2 and 3, 
and a proline rich region, that is basic.  The projection domain is so named because it 
projects away from the microtubule and can interact with cytoskeletal elements, the 
plasma membrane (12, 13), or tau on other microtubules (14). The second domain is 
the microtubule binding domain that includes the 3 or 4 microtubule binding repeats 
and the C-terminus of tau.  The microtubule binding repeats are highly conserved 18 
amino acid (aa) repeats that begin with the amino acid sequence VXSK, separated by 
less conserved 13 or 14 amino acid inter-repeat regions (5, 8, 15, 16).  One 18aa 
repeat is sufficient for tau to promote microtubule assembly in vitro (17).  These 
repeats bind microtubules through a number of weak amino acid groupings and the 
repeats have flexible linker regions to allow tau to bind tubulin in multiple 
conformations (18).  274KVQIINKK281 in inter-repeat region between microtubule 
binding repeat 1 and microtubule binding repeat 2  is present only in 4R isoforms and 
contributes to the higher binding affinity of tau for tubulin than 3R isoforms that lack 
this sequence (19, 20).   
 
1.1.5 Tau interacts with tubulin 
The main function of tau is to bind to tubulin and promote assembly into 





at approximately 1 tau per 4-5 tubulin dimers, implying one microtubule binding 
repeat of tau per tubulin dimer (21).  Tau binds to the C-terminal region of tubulin as 
determined by subtilisin digestion (22).  Digestion of both α and β tubulin with 
subtilisin resulted in two fragments per tubulin monomer, the smaller of which 
corresponds with the C-terminal domain of  α- or β- tubulin (23).  When tau was 
incubated with the two tubulin fragments, tau was able to bind only to the smaller C-
terminal fragment as determined by column chromatography of tau and [P3PH] 
tyrosinated tubulin (22).  Additionally, tau failed to assemble tubulin that lacks this 
C-terminal region, but assembles full length tubulin indicating this region is required 
for tau and tubulin to interact (22).  Mutations of charged lysines 274, 280, 281, 
located in the microtubule binding repeat region of tau, can reduce binding of tau to 
the C-terminus of tubulin, which indicates electrostatic interactions play an important 
role in binding (24).  In addition, hydrophobic regions in the MTBR of tau seem to 
play a role in mediating binding (25, 26).  By deleting or mutating these hydrophobic 
regions, tau has a reduced affinity for microtubules (26).  This indicates the 
mechanism by which tau and tubulin interact is very complex and the multiple 
interactions involved could have compensatory effects to prevent a loss of interaction 
between tau and tubulin.   
 
Overall, tau is transported along the axon, primarily anterogradally, at a rate similar to 
tubulin (~0.003 µm/s) (27).  Over short-intermediate distances tau rapidly diffuses in 





by association with microtubule fragments (29).  The exact mechanism of tau 
transport along the axon is unclear, however, due to the exchange rate of tau on 
microtubules, which blurs visualization of fluorescently labeled tau.  Phosphorylated 
tau, which has a reduced affinity for microtubules, is found to be less concentrated 
along the microtubules, and is able to diffuse at a higher rate (~11 µm2/s) than non-
phosphorylated tau (28).  Aggregated tau, similar to that of AD tau, can move 
bidirectionally at a fast-axonal transport rate (~0.3 µm/s) (29).  In AD, aggregated tau 
is found in somatodendritic compartments, although the mechanism of how 
aggregated tau is transported to these compartments has not been elucidated (30).  
This observation could occur when aggregated tau, which moves faster (28), and 
inhibits kinesin more than dynein (31), results in a net retrograde transport.  
Determination of influences on tau/microtubule interactions could lead to the 
elucidation of how tau affects transport of itself and other protein along an axon.   
 
Tau binding to tubulin is regulated by phosphorylation of tau.  To date, 71 of a 
potential 85 serine, threonine and tyrosine sites on tau have been shown to be 
phosphorylated in vivo under either normal or diseased conditions.  This large 
proportion of sites can be phosphorylated by over 30 kinases (discussed later; see 
section 1.5).  Alternatively, there are three known phosphatases that work to regulate 
the phosphorylation state of tau (see 1.5).  Tau is normally phosphorylated to regulate 
its affinity for microtubules (32-38).  Phosphorylation at residue S262, in the 





(39), albeit not completely (40).  Tau phosphorylation is dramatically different 
between early development and adult states.  The dynamic nature of phosphorylation 
of tau isoforms plays a major role in the structure and differentiation of neurons in 
neurite outgrowth, axonal extension, and polarity by regulation of microtubule 
properties such as stability, spacing, and length.  During fetal development, 0N3R is 
phosphorylated at a higher level than what is found on normal post-natal tau isoforms 
(41, 42).  It makes sense then that 0N3R tau is highly phosphorylated to allow these 
processes to occur, and once a neuron has fully differentiated, to lower the 
phosphorylation state of tau to be less dynamic.  In AD, abnormal phosphorylation 
occurs and plays a role in the progression of the disease; however, it is unknown the 
exact mechanisms by which this occurs (Figure 1.2).  If a neuron has too much 
phosphorylated tau, it may occur because the cell wants to change its organization, 
which it cannot achieve and results in a diseased state.  The role phosphorylation on 




Most proteins, when synthesized from the ribosome, adopt a folded structure.  Protein 
folding is achieved by attaining the most thermodynamically stable state.  This 
includes the internalization of hydrophobic regions and externalization of hydrophilic 
regions to the solvent.  To reach this state, the protein usually passes through a series 






Figure 1.2 Overview of tau phosphorylation leading to dysfunction.  (adapted 
from Dr. Lester Binder).  Tau normally binds to and stabilizes microtubules in the 
axon of a neuron.  Upon hyperphosphorylation, tau undergoes a conformational 
change that increases its propensity to polymerize into filaments.  The exact 
mechanism for how phosphorylation causes conformational changes and increased 
polymerization is unknown.  Reducing the concentration of bound tau to microtubules 
can lead to destabilization of the microtubule, however, the mechanism is unknown in 
a neuron and could be compensated for by other microtubule associated proteins.  The 
mechanism by which polymerized tau and/or microtubule disruption lead a neuron to 





from molecular chaperones that bind to exposed hydrophobic regions (see section 
1.6).  If these hydrophobic regions are left exposed, there is a possibility of 
interaction with exposed hydrophobic regions on other proteins resulting in protein 
aggregation. 
 
A class of diseases, termed amyloidoses, results from the deposition of misfolded 
proteins into organs and tissues.  These proteins that have misfolded and escaped 
degradation result in self aggregation into insoluble fibrous structures termed amyloid.  
Nearly every protein has the ability to form amyloid (43). However, to date about 26 
amyloid diseases exist, such as AD, type II diabetes and mad cow disease (reviewed 
in (44)).  The proteins involved in these diseases vary in their normal folding and 
function.  However, in their amyloid states, they all share characteristics, such as 
structural similarities, that make them indistinguishable from each other.   
 
1.2.2 Formation 
Amyloidogenic proteins characteristically form cross β-sheet secondary structure that 
aggregate into fibers as determined by Congo red staining (45) and X-ray diffraction 
(46).  Cross β–sheet structure is defined as β-sheets aligned parallel to each other and 
perpendicular to the axis of the fibril (Figure 1.3).  The β-sheets can either adopt a 
parallel or antiparallel orientation and the fiber is unbranched and helical in nature.  
The fiber is stabilized by axial hydrogen bonds that occur between the peptide 






Figure 1.3 General Amyloid structure.  (A-D)  Four ways β sheets could stack in an 
amyloid fibril.  (A, B) parallel β sheets, (C, D) antiparallel β sheets.  Each red and 
blue sheet is part of the same monomer, indicated by the joining lines, and different 
monomers interact in the direction of fiber formation, as denoted by the arrow.  
Hydrogen bonding of (E) parallel β sheets or (F) anti-parallel β sheets.  Based upon 
X-ray diffractions, the distance between R-groups for tau fibers is 6.9 Ǻ, 
corresponding with an anti-parallel conformation.  Alternatively, each red and blue 





Despite the overall structure, the mechanism of fiber formation is unknown.  This is 
the overall question we are trying to answer, and the work done here is a good 
primary step in the direction of determining the mechanism of amyloid fiber 
formation. 
 
Aggregation of protein to form amyloid fibrils is thought to follow a nucleation-
elongation mechanism.  This means monomer aggregates to form a nucleus and upon 
reaching a certain nucleus size.  Addition of subsequent monomers will be added to 
elongate into fibrils.  It is unknown whether addition of monomer in the elongation 
phase is unidirectional or bidirectional.  The concentration of monomer required to 
form a nucleus is defined as the critical concentration for polymerization.  At protein 
concentrations below the critical concentration, nucleation does not occur, but once 
the critical concentration is reached, polymerization proceeds at a constant rate until 
the monomer pool reaches the critical concentration and steady state is achieved, 
meaning no further polymerization occurs.  This nucleation mechanism has been 
shown to occur for a variety of proteins such as prion protein (PrP), amyloid β (Aβ), 
tau and α-synuclein (50, 51).  The formation of the nucleus occurs very slowly in vivo 
and in vitro in the absence of any external influences.  However, reduction of the 
critical concentration for nucleation, for use in studying polymerization in a relative 
short time period, can be achieved by addition of oligomer seeds (52) or inducer 
molecules (51).  The critical concentration of monomer in the presence of these 





filament formation.  The elongation phase can also be affected by a number of factors.  
Mutations (53-55), protein concentration (51), pH changes (56-58), post-translational 
modifications (59, 60), and interaction with other molecules (61-63) or proteins (64) 
can alter the rate of elongation.  Because of these factors, we would predict that local 
variations to the environment, such as changes in protein concentration, buffer or 
interactions with other factors in a cell and in vitro would have consequences on the 
formation of tau filaments.  Therefore, one of our overall goals is to elucidate the 
impact of the molecular environment on tau filament formation in vitro, as we can 
more precisely control the environment. 
 
1.3 Tau Dysfunction 
Most proteins have a distinct natively folded state and in order to form amyloid fibers, 
need to undergo unfolding and misfolding into a conformation that allows β-sheet 
structures to interact.  A second type of protein that can form amyloid undergoes a 
different transition.  Instead of being folded in a distinct natively folded state, natively 
unfolded or intrinsically disordered proteins, such as tau, α-synuclein and Aβ, exist 
without discernable structure and only need to adopt a partially misfolded state in 
order to form amyloid fibers (65).  Assembly of tau into amyloid fibers can result in 
paired helical filaments (PHFs) or straight filaments (SFs).  However, it is unknown if 
PHFs are the result of SF combination or through a distinct mechanism.  Studies 
examining recombinant tau protein in the form of PHFs or SFs in vitro have shown 





vitro studies can model the diseased state and have a direct impact on AD research.  
PHFs have two distinct traits, a fuzzy coat (66) and a pronase resistant core.  The PHF 
core, as analyzed by mass spectroscopy, is composed of two main regions of tau, 
encoded by exons 10 and 11 (67).  This implies the coat is composed of the remainder 
of tau (N- and C-terminal regions), projecting away from the filament.  The minimal 
sequence needed to generate filaments has been mapped to 275VQIINK280, located in 
exon 10 between MTBR1 and MTBR2 and 306VQIVYK311, located in exon 11 
between MTBR2 and MTBR3.  The 275VQIINK280 is absent in 3-repeat tau isoforms, 
which is thought to contribute to why 3R isoforms polymerize less well than 4R.  The 
~10 residues following these two regions can form helical structure and associate 
with phospholipid micelles.  These negatively charged, phosphate covered micelles 
are thought to mimic the microtubule surface and could be used as a nucleation 
source for tau polymerization (68).  While most tauopathies are associated with non-
mutated tau, certain mutations, such as ΔK280 and P301L (naming based upon 2N4R 
tau), increase the propensity of beta sheet formation in these hexapeptides (69).  
Conversely, proline substitutions in the 275-280 and 306-311 regions can inhibit β-
sheet formation and aggregation (69).  Being able to correlate results of in vitro tau 
polymerization with in vivo studies allows us to more precisely alter tau, through 
post-translational modifications, and conditions for polymerization.  These controlled 
experimental manipulations will allow us to make more accurate conclusions about 
how tau polymerization occurs.  This dissertation will examine the role of specific 







Tauopathies are a class of brain disorders that are characterized by abnormal tau 
aggregates.  These aggregates manifest themselves in various forms in various 
diseases talked about briefly in this section.  However, there are some common traits 
these tau aggregates share.  Normal tau phosphorylation is beneficial for regulation of 
its affinity for microtubules.  Under certain conditions, tau can become abnormally 
“hyperphosphorylated” and lose the ability to bind to microtubules.  This creates a 
pool of tau that, if not degraded by the cell, can aggregate to form amyloid fibrils.  
Hyperphosphorylation refers to increased phosphorylation of tau such that it can 
induce a SDS-resistant conformational change when visualized by SDS-PAGE.  Tau 
isolated from tauopathies is mainly hyperphosphorylated and insoluble.  This is 
interesting because phosphorylation decreases hydrophobicity, which is thought to be 
a contributing factor to tau aggregation.  The question of how hyperphosphorylation 
promotes tau aggregation is a major focus of the field.  One large and interesting 
difference between tauopathies is despite similar soluble tau levels to normal aged 
brains, the various tauopathies have different amounts of the tau isoforms in the 
insoluble form associated with the tauopathy (Table 1.1).  This indicates that 
something in the cell promotes or prevents the inclusion of certain tau isoforms into 
the insoluble fractions.  These events could include post-translational modifications 
and/or interactions with other proteins.  In this section, general similarities and 





why examining tau isoforms and post-translational modifications are important for 
understanding tau biology.  By determining how the various tau isoforms polymerize, 
we can start to understand the etiology of various tauopathies. 
 
1.4.2 Alzheimer’s disease (AD) 
The most common form of dementia is Alzheimer’s disease accounting for 60-80% of  
cases (70).  First described in 1907 by Alois Alzheimer (71), the disease now affects 
5.4 million Americans and is the 6th leading cause of death in the United States (70).  
The most common symptoms in patients are a decline in the ability to remember 
names and events, eventually leading to a decline in the ability to perform daily 
functions and loss of motor skills.  Compared to normal aged brains, there is a 
quantifiable increase of neuronal loss of hippocampal neurons in AD brains, a region 
high in tau pathology (72).  Likewise rapid atrophy of the brain is elevated in AD as 
compared to normal aged brains (73)  Pathologically, there are two hallmarks that 
define the AD brain.  Extracellular senile plaques are composed of Aβ protein, which 
is processed from amyloid precursor protein and are found located near synapses.  
There are multiple types of plaques, but neuritic plaques are considered the most 
pathologically relevant (74).  Neuritic plaques stain with Congo red, an amyloid stain, 
and have a dense core and a halo of Aβ amyloid.  Plaques composed of Aβ do not 
seem to originate in a particular region of the brain and can be found all over the 
cerebral cortex, but are also seen in normal aged patients (75).  The second 





composed of hyperphosphorylated tau protein.  Tau from NFTs is known to be 
hyperphosphorylated because NFTs stained with both antibodies to anti-PHF tau, and 
antibodies to normal tau.  However, upon tau dephosphorylation, a greater amount of 
normal tau staining is observed (76-79).  Tau isolated from NFTs in AD brains can be 
found as both paired helical filaments (PHFs) (80) and straight filaments (81).  PHFs, 
are composed of entwined tau filaments, and are insoluble inclusions that can be 
isolated from affected neurons in various tauopathies.  Insoluble means after addition 
of detergents, such as sarkosyl, where normal proteins would denature, the filaments 
stay together.  This is a useful property, as isolation of insoluble aggregates can be 
achieved through detergent treatment and ultracentrifugation, resulting in insoluble 
tau in the pellet and soluble tau in the supernatant (see Table 1.1).  In 1986, PHFs 
isolated from AD brains contained mainly hyperphosphorylated tau, as determined by 
staining with antibodies specific to phosphorylated tau (P-tau) (82, 83).  When AD 
brain tubulin was assembled into microtubules, only tau from aged-matched controls 
and DEAE-dextran, a polycation that mimics tau in stimulating microtubule assembly, 
was able to accomplish assembly, not PHF tau.  This indicates hyperphosphorylated 
tau from AD brain tissue has a lowered affinity for microtubules compared to aged 
matched control tau (84).   
 
Tau is normally found in the axon, but in AD, is aggregated and missorted to 
somatodendritic compartments (30).  While many neurons that contain NFTs are still 





stress response protein (85). Neurons containing NFTs that die and disintegrate leave 
proteolytically degraded “ghost” tangles that lack the C- and N-terminus, indicating 
that processing of filamentous tau could result in increased tau insolubility.   
 
The type and severity of AD is closely associated with NFT load (86-88).  There are 
two types of AD, familial (early onset) and sporadic (late onset).  Familial AD (FAD) 
accounts for less than 5% of AD cases and occurs in patients younger than 65.  FAD 
is usually associated with mutations in the amyloid precursor protein (APP), 
presenilin 1, and/or presenilin 2 genes that are all involved with generating Aβ 
pathology.  Sporadic AD (SAD) accounts for almost all cases of AD.  The largest risk 
factor for developing SAD is age.  However, apolipoprotein E isoform 4 (ApoE4) has 
been found to be associated with increased risk of AD development (89).  Having one 
ApoE4 allele increases the risk of SAD, while having two alleles increases the risk 
even further, but does not guarantee AD development.  AD is not associated with any 
mutations in the tau gene or upregulated expression of any isoform.  This indicates 
that all tau pathologies are a result of post-translational modifications and interactions 
with other molecules or proteins.  We propose that these post-translational 
modifications and interactions with other molecules will have diverse effects on tau 








1.4.3 Pick’s Disease (PiD) 
Pick’s disease is characterized by changes in personality and social behavior (90).  
The pathological hallmark characteristic of PiD are intracellular Pick bodies 
composed primarily of 3R hyperphosphorylated tau, although 4R tau is also present 
in smaller amounts (91).  This is different from AD where all six isoforms are 
incorporated into the pathology, despite both AD and PiD having similar levels of 
soluble tau isoform expression (30).  Pick bodies are found in the frontal and 
temporal cortex and hippocampus as spherical cytoplasmic inclusions mainly in 
neurons.  PiD is considered a sporadic tauopathy, even though tau mutations are 
associated with the disease.  However, the pathology between non-mutated and 
mutated forms are indistinguishable (92).  Mechanisms for 3R tau polymerization in 
vitro could lead to the elucidation of how PiD progresses, and will be examined in 
this dissertation. 
 
1.4.4 Progressive supranuclear palsy (PSP) and corticobasal 
degeneration (CBD) 
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) can be 
grouped together, because unlike in AD, where tau is found almost exclusively in 
neurons, PSP/CBD tau is also found in glial cells.  Unlike AD which has mixed 
incorporation of 3R and 4R isoforms in insoluble aggregates, PSP/CBD brains have a 
higher amount of 4R tau than 3R tau in these aggregates.  This is interesting because 





extracts, indicating different mechanisms by which tau isoforms can aggregate (30).   
In PSP, glial cells containing tau are called tufted astrocytes (astrocytes) or coiled 
bodies (oligodendrocytes) (93-95).  NFTs found in PSP are composed of straight 
filaments and long-period twisted filaments of predominately 4R tau (96-98, 99 ).  In 
CBD, neuropil threads composed of tau are found located more in the cortex as 
compared to PSP where tau pathology is found in the brainstem (100-103).  CBD tau 
is found aggregated in the form of PHFs and SFs (94, 104).   
 
1.4.5 Frontotemporal dementia with parkinsonism associated with 
chromosome 17 (FTDP-17) 
It was not until mutations in tau associated with neurodegenerative disease were 
discovered that tau gained wide acceptance as causing dementia and 
neurodegeneration.  Most mutations in tau result in similar phenotypes to those of the 
sporadic tauopathies (30).  FTDP-17 is a class of familial neurodegenerative 
tauopathies in which mutations in tau are associated with disease.  A variety of 
symptoms can be associated with FTDP-17 such as changes in behavior, cognition 
and motor function.  These diverse symptoms are due to the many types of mutations 
in tau associated with FTDP-17.  32 different mutations have been observed in over 
100 families (105).  Mutations either change the way tau is spliced and alters the ratio 
of 3R and 4R tau (106-115), the way tau interacts with microtubules (11 , 116) and 
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Table 1.1 Summary of differences between tauopathies.  A large difference 
between tauopathies is the inclusion of various levels of tau isoforms in insoluble 





tau associated with FTDP-17, the research presented can be applied to future studies 
examining how mutations on tau can affect the wild-type properties. 
 
1.5 Tau phosphorylation 
Tau is known to be post-translationally modified by phosphorylation, glycosylation, 
ubiquitination, oxidation, nitration, glycation and truncation (reviewed in (124)). The 
interplay of the various modifications is still unknown, meaning does phosphorylation 
cause changes in glycation, or do changes in glycation cause subsequent changes in 
phosphorylation.  However, the most studied single post-translational modification of 
tau is phosphorylation at serine and threonine residues.  Tau has 85 potential 
phosphorylation sites, with 71 being described under pathological or physiological 
conditions and being controlled by over 30 kinases that can be divided into three 
groups (reviewed in (60, 125)).  The first group includes kinases that are proline 
directed to serine and threonine residues (S/T-P) and include CDK2/5 (126), MAPK 
(127) and GSK-3β (128).  The second group includes non-proline directed kinases 
such as tau-tubulin kinase, casein kinase, MARK, PKA and PKC that phosphorylate 
serines and threonines (128-135).  The third group is tyrosine protein kinases which 
include Src (136) and C-Abl (137).  Phosphatases that dephosphorylate tau include 
PP1, PP2A, and PP2B (138-143).  It is thought PP2A is the major phosphatase 
involved in modifying tau as inhibition of PP2A, but not PP1 and PP2B, results in 
increased tau hyperphosphorylation and accumulation in rat brains (144, 145).  





FTDP-17 patients can decrease PP2A binding, leading to increased phosphorylation 
and aggregation when examined in vitro (146).  Hyperphosphorylated tau can 
undergo conformational changes that alter phosphatase binding by preventing or 
making accessible the sites of phosphorylation.  This is supported by evidence 
showing chaperones can alter tau conformation and promote phosphatase activity 
(reviewed (147)).  This is important because having too many phosphorylation 
changes could create an irreversible conversion of tau to its misfolded state.  By 
determining how phosphorylation changes affect tau, we can potentially determine a 
way to stop the conversion of tau into an altered conformation earlier. 
 
Phosphorylation of tau is known to regulate microtubule binding (37, 148) and GSK-
3β has been shown to accomplish this regulation in vitro and in cell assays (149, 150).  
Induced over expression of GSK-3β in mice has shown free tau accumulates in 
hippocampal neurons indicating GSK-3β as a major kinase involved in tau 
phosphorylation and aggregation (151, 152).  Investigation into the role of GSK-3β 
on tau function and dysfunction will be addressed in Chapter 3. 
 
Tau is normally phosphorylated at 2-3 moles of phosphate per mole of tau, but in AD 
is hyperphosphorylated to 5-9 moles of phosphate per mole of tau (32).  As 
mentioned previously, hyperphosphorylated tau is found in NFTs.  The majority of 
tau phosphorylation occurs at sites outside MTBRs and can decrease tau-microtubule 





causes more drastic changes to the microtubule binding of tau (~10 fold decrease in 
microtubule affinity as compared to non-phosphorylated tau) (40, 155).  However, 
complete inhibition of microtubule binding has not been observed with 
phosphorylated tau.  Alternatively, phosphorylation of tau can inhibit microtubule 
assembly while not changing microtubule binding affinities (153, 154, 156).  This 
indicates specific roles for phosphorylation at various sites by the various kinases.  
Understanding the precise role each kinase plays in regulating tau/tubulin interactions 
is key to understanding the progression of tauopathies.  While we cannot address all 
the kinases involved in the scope of this dissertation, we will focus on GSK-3β, as it 
is most widely believed to play the largest role in disease progression (see Chapter 3).   
 
Hyperphosphorylated tau is found in different states in different tauopathies, 
indicating different mechanisms of phosphorylation.  Missense mutations in tau 
present in FTDP-17 can cause a decrease in microtubule affinity resulting in 
accumulated phospho-tau.  PP2A has a decreased affinity for these mutated tau forms, 
resulting in increased phospho-tau (146).  Aβ protein, the other major pathological 
protein in AD has been shown to downregulate PP2A, resulting in increases in 
hyperphosphorylated tau (157, 158).  Since tau aggregation correlates better with the 
severity of dementia, it is possible that small amounts of Aβ, which have not 
accumulated into plaques and therefore are unable to be correlated to severity, could 
downregulate PP2A, increasing tau phosphorylation and aggregation.  The results 





only in the normal function of tau in regulating microtubule dynamics, but also as a 
regulator of tau aggregation.  We have investigated the role of GSK-3β on tau 
function and dysfunction in order to determine if GSK-3β alone is sufficient to cause 




In order to function properly, a protein needs to be folded into a conformation that 
confers activity.  A class of cellular proteins, termed molecular chaperones, facilitates 
proper folding of nascent proteins and refolding of proteins that have undergone 
partial or total denaturation to prevent these proteins from aggregating.  In the case a 
misfolded protein cannot refold into its native conformation, chaperones can aid in 
their degradation.  Chaperones are also involved in protein translocation across 
membranes, vesicular transport regulation and multimeric complex formation and 
protein destruction (159-161).  While some molecular chaperones are constitutively 
expressed and active, groups of chaperones are elevated in response to cellular stress.  
In 1962, a paper described “puffs” on DNA in Drosophila busckii after heat stressing 
the flies (162).  These puffs were determined to be proteins that were only expressed 
in response the heat stress and thus were termed heat shock proteins.  It was later 
discovered other cellular stresses also produced a small number of these new stress-






1.6.2 Heat shock protein 70 ( Hsp70) 
The most evolutionarily conserved heat shock protein is Hsp70 (167-169).  DnaK, the 
E. coli homologue, is ~60% identical in sequence to mammalian Hsp70.  The Hsp70 
family in mammals contains 8 different genes that differ in primary sequence by up to 
48%, and also differ by expression levels and localization (170).   Most Hsp70 family 
members are localized in the cytosol/nucleus, except for Hsp70-5 which is found in 
the lumen of the ER and Hsp70-9 which is found in the mitochondrial matrix 
(reviewed in (171)).  What makes the different gene products part of the same protein 
family is the common structure domains.  Hsp70 family members consist of an 
ATPase domain, a protease sensitive site, a substrate binding domain (SBD), a 
variable region and an EEVD motif where co-chaperones can bind (161, 170, 172).  
The major Hsp70 genes are HSPA1A (encoding Hsp70-1a) and HSPA1B (encoding 
Hsp70-1b) which differ by only two amino acids (173).  Hsp70-1a/b proteins are 
upregulated in response to stress, but are present at low levels that vary with cell type 
and cell cycle (174, 175).  HSPA1A/B knockout mice are viable, but have increased 
susceptibility to many stress related disorders such as UV light stress and cerebral 
ischemia (176-178).  This dissertation will focus on HSP70-1a protein because it is 
implicated to play a large role in AD (see 1.6.4). 
 
1.6.3 Hsp70 Mechanism of action 
Hsp70 generally acts by hydrolyzing ATP in the ATPase domain to increase binding 





which ATP binds.  These subdomains are flexible and can alter conformation 
between ATP, ADP or nucleotide-free states (179).  The substrate binding domain 
also has two subdomains, the bottom subdomain has a hydrophobic groove where the 
substrate binds and the top subdomain is an α–helical lid that can come in closer 
proximity to the groove portion (180).  The hydrophobic groove is where binding of 
exposed hydrophobic patches of unfolded or misfolded proteins occurs (180).  The 
linker region between the two domains seems to confer signals between the two 
domains.  In the ATP bound state, the SBD enters a more open conformation, and 
upon substrate binding, ATP is hydrolyzed to “close” the lid of the SBD (159).   
 
1.6.4 Hsp70 in AD 
The initial indication the heat shock response could act as a control mechanism in AD 
was implicated in 1988 when analyzing the promoter of APP, the protein from which 
Aβ protein is cleaved, and discovering a consensus binding site for heat shock control 
element binding proteins (181).  Since then, numerous heat shock proteins have been 
found to be elevated in AD hippocampal brain tissue compared to age matched 
controls (182).  In particular, Hsp70/90 are found upregulated in specific 
hippocampal neurons devoid of tau aggregation (183).  Other chaperones such as 
Hsp27, Hsp70 and carboxy terminus of Hsc70 interacting protein (CHIP) can 
indirectly dephosphorylate and degrade abnormal tau in cell models (183-185).  
Upregulation of Hsp70/90 can increase tau interactions with microtubules and 





heat shock cognate 70 (Hsc70), is 86% identical to Hsp70 and both have been shown 
to interact with tau protein (186).  Finally, addition of Hsp70 and/or Hsp40, a known 
Hsp70 co-chaperone, to heparin mediated tau polymerization in vitro resulted in 
decreased tau aggregation (187). 
 
Taken together the heat shock response seems to play a major role in preventing tau 
mediated neuronal damage and degeneration.  We have examined the influence of 
Hsp70 on tau to inhibit its aggregation in vitro.  In addition, even though Hsp70 can 
increase tau localization to microtubules in cells, it may be indirectly accomplishing 
this.  We examined if Hsp70 allows tau to interact with tubulin to promote or inhibit 
microtubule assembly.  
 
1.7 Overall summary and hypothesis  
We have a set of tools to examine tau polymerization and microtubule interactions in 
vitro, and based upon the current literature, believe this will be applicable to the 
processes that occur in AD.  We know tau can polymerize in vitro in the presence of 
inducer molecules, but we are uncertain how this occurs.  Likewise, most research 
focuses on how 2N4R tau polymerizes, since 2N4R tau is the longest isoform and 
includes all residues making comparison of other isoforms easy because differences 
can then be attributed to loss of exons 2, 3, and/or 10.  However, different 
mechanisms by which the other tau isoforms polymerize may exist.  We believe this 
because there is a significant difference between tau isoforms when comparing their 





isoforms are missing a functional microtubule binding domain, which has been shown 
to play a large role in both microtubule affinity, and polymerization.  We also seek to 
determine how phosphorylation affects the characteristics of tau isoforms, based 
again on the fact that the isoforms vary in length that could affect folding and whether 
tau isoforms can adopt conformations that promote or hinder aggregation and 
microtubule assembly.  Finally, since Hsp70 has been implicated as a protein that 
could aid in preventing tau accumulation, we have investigated whether Hsp70 can 
directly act on tau isoforms to prevent aggregation and whether this potential 





Chapter 2- Methods 
 
2.1 Tau expression and purification 
Individual tau isoforms in pT7C vectors were a gift from Dr. Jeff Kuret (Ohio State 
University), and were described previously (188).  For each isoform, the pT7C vector 
was transformed into BL21 (DE3) competent cells and plated on LB-agar with 
ampicillin.  An individual colony was used to seed overnight 80 ml cultures of LB-
broth with ampicillin in Erlenmeyer flasks at 25 oC.  Once an OD600 close to 0.5 was 
achieved, three 600 ml wide bottom Fernbach flask containing LB-broth with 
ampicillin were inoculated with 20 ml of the overnight culture at 37 oC until an OD600 
of around 0.7 was reached.  Cells were induced to express tau with 500 mM IPTG 
(Calbiochem) at a final concentration of 1 mM at 37 oC for 2 hours.  Cells were then 
centrifuged at 5000 RPM at 4 oC for 10 min in a Sorvall SLA-3000 rotor.  The 
supernatant was discarded and cells were resuspended with 5 ml of ice cold lysis 
buffer (500 mM NaCl, 10 mM Tris base, 5 mM Imidazole, pH 8) per bottle.  All 
resuspensions were pooled into a 50 ml conical tube and protease inhibitors (aprotinin, 
pepstatin A, leupeptin, phenylmethanesulfonylfluoride (PMSF)) were added to 1x, 
along with DTT (0.1 mM final).  Cells were lysed three times using a French pressure 
cell (Thermo).  Brij 35 (0.1% final) and more PMSF were then added and the lysate 
was centrifuged at 11,500 RPM in a Sorvall SS-34 rotor, 30 min at 4 oC.  The 
supernatant was purified by Nickel affinity chromatography using an ÄKTA FPLC 
(GE Healthcare).  Collected fractions after elution with elution buffer (500 mM NaCl, 





polyacrylamide gels.  Fractions containing tau were pooled and concentrated to 2-4 
ml using an ultrafiltration stirred cell (Millipore) with a 30,000 MWCO YM30 
cellulose filter.  Concentrated samples were purified by size exclusion 
chromatography over a Superdex 200 column using the same ÄKTA FLPC (GE 
Healthcare).  Fractions were analyzed by SDS-PAGE to determine where tau was the 
most abundant, and the least contaminated with other proteins.  Usually, three 
fractions are pooled (6 ml total), DTT to 0.1 mM is added and protein is aliquoted 
into 75 µl, and stored at -80 oC.  Tau protein concentration was determined using a 
commercially available BCA assay (Pierce), using BSA as the standard.  Briefly, 
BSA at 2 mg/ml was used to generate a standard curve, and tau was diluted from 20x-
2x and compared to the standard curve.  Only absorbance readings for tau that fell 
within the standard curve were used, and the assay was repeated three times and 
averaged to determine a protein concentration.  This concentration was confirmed by 
running the new tau prep against old tau preps of known concentration by SDS-
PAGE.  Tau molecular weights with a histidine tag, reported in (188), were used for 
future experiments and are as follows: 2N4R (48,013 Da), 2N3R (44,766 Da), 1N4R 
(45,130 Da), 1N3R (41,883 Da), 0N4R (42,170 Da), 0N3R, (38,923 Da). 
 
2.2 Arachidonic acid (ARA) induced tau polymerization (Chapter 3 
Part 1) 
2N4R tau (0-4 µM) was incubated in polymerization buffer (10 mM Hepes, pH 7.64, 





(0-300 µM; the ethanol vehicle concentration was constant at 3.75% for all reactions) 
at room temperature, overnight (~20 hours).   
 
2.3 Heparin induced tau polymerization (Chapter 3 Part 1) 
Low salt (50 mM NaCl) 2N4R tau (0-4 µM), was incubated in low salt 
polymerization buffer (10 mM Hepes, pH 7.64, 15-40 mM NaCl, 0.1 mM EDTA and 
5 mM DTT)  with various concentrations of heparin (0-6.25 µM, made in water) at 37 
oC, overnight (~20 hours).  The higher temperature was used as heparin induced 
polymerization proceeds more slowly than ARA induced, but is accelerated at higher 
temperatures. 
 
2.4 ARA induced tau polymerization (Chapter 3 Part 2) 
The final concentration of components in a polymerization reaction of 200 µl using 
ARA were: 2 µM Tau, 10 mM Hepes pH 7.64, 100 mM NaCl, 0.1 mM EDTA, 5 mM 
DTT, and 0-150 µM ARA (concentration of ethanol carrier was kept constant at 
3.75% for all reactions).  Reactions were incubated at 23 oC for 18 hours in a tabletop 
incubator.  Room temperature in Chapter 3 Part 1 fluxuates, but averages 23 oC and 
this temperature was used to maintain consistency throughout experiments. 
 
2.5 Heparin induced tau polymerization (Chapter 3 Part 2) 
The final concentrations of components in a heparin polymerization reaction of 200 





mg/ml–0.024 mg/ml).  Reactions were incubated at 37°C for 18 hours in a tabletop 
incubator.  Data for one of the three trials for 2N4R with 0.006 and 0.018 mg/ml 
heparin, 1N4R with 0.024 mg/ml heparin, and 0N4R with 0.018 mg/ml heparin were 
found to be inconsistent (greater than 33% different) from the other data and were not 
included in the graphs. 
 
2.6 Right angle laser light scattering (LLS) 
After incubation, tau polymerization reactions were assayed by right angle laser light 
scattering.  Reactions were placed into 5 x 5 mm fluorometer cuvettes (Starna) and 
reactions in Chapter 3 were illuminated with a 5 mW solid state 475 nm laser (B & W 
Tek), while reactions in Chapter 4 were illuminated with a 5mW solid state 532 nm 
laser (B&W Tek).  The original laser broke and was replaced with a different 
wavelength.  The resulting images of scattered light perpendicular to the incoming 
light were captured with a digital camera (Sony XC-ST270); imported into Adobe 
Photoshop and using the histogram function of the program assigned an arbitrary 
value where increases correspond to more polymerization (189). 
 
2.7 Thioflavine S (ThS) Fluorescence 
After incubation, tau polymerization reactions were assayed by ThS fluorescence, a 
planar aromatic dye that binds tau polymer, but not monomer.  ThS was added to 





excitation of 440 nm and λ emission of 520 nm in 96-well plate format in a Cary 
Eclipse fluorescence spectrophotometer (Varian) (189). 
 
2.8 Transmission Electron Microscopy (TEM) 
Polymerization reactions for Chapter 3 were prepared for TEM by methods 
previously described (189). Reactions for ARA were diluted 1:10 and reactions for 
heparin were diluted 1:5.  After dilution, reactions were fixed with a final 
concentration of 2% glutaraldehyde, placed on formvar-carbon coated grids (Electron 
Microscopy Sciences), and stained with 2% uranyl acetate (Electron Microscopy 
Sciences) (189). Prepared grids for Chapter 3 were viewed with a JEOL 1200 EXII 
electron microscope, and images were captured with the MegaViewII imaging system 
(Soft Imaging System).  Tau filament lengths were measured from digitized electron 
micrographs using the Optimas analytical imaging software (Media Cybernetics).  
Frequency distributions of filament lengths were generated by placing filament 
lengths into 50 nm bins with the center of the first bin at 25 nm.  The number of 
filaments per bin was multiplied by the bin center to generate the approximate mass 
of filaments within a given length of filaments.  The mass per bin was then divided by 
the total filament mass to give a percent of total mass for each range of filament 
lengths (189). Prepared grids for Chapter 4 were diluted 1:10, and were viewed on a 






2.9 ARA and Heparin induced tau polymerization kinetics (Chapter 3 
Part 1) 
2N4R tau (0.5-4 µM) was incubated at optimal, limiting and inhibitory ratios of ARA 
and heparin.  Reactions were followed by the fluorescence increases in the presence 
of 20 µM ThS using a Flexstation II fluorometer microplate reader (Molecular 
Devices Corporation).  The Flexstation automatically adds ARA and reads the 
reactions immediately to reduce any lag time introduced by human pipetting.  Data 
was fit to a single phase exponential association equation using GraphPad Prism 
software.  The data for optimal ratios of ARA were fit using a mathematical model 
developed for the kinetics of actin nucleation and polymerization (190) by first fitting 
the 4 µM tau curve for values of n, k+, and Kn-1 and then using these values to fit the 
data from the other protein concentrations. 
 
2.10 Glycogen synthase kinase 3β (GSK-3β) phosphorylation of tau 
isoforms 
GSK-3β (Sigma Aldrich) phosphorylation reactions (25 µL) of each tau isoform 
contained 16.66 μM tau, 0.018 U GSK-3β per pmol of tau in buffer (40 mM HEPES, 
pH 7.64, 5 mM EGTA, 3 mM MgCl2, and 2 mM ATP).  One unit is defined as the 
amount of GSK-3β required to catalyze the transfer of 1 pmol phosphate to tau in 1 
min at 30°C in a reaction volume of 25 µL.  Reactions were incubated for 20 hours at 
30°C (191). The degree of phosphorylation was determined by examining the 





2.11 ARA induced polymerization of GSK-3β phosphorylated tau 
isoforms 
25 µL phosphorylation reactions of the individual isoforms (see section 2.10) were 
diluted into ARA containing polymerization reactions, as previously described in 
(191).  
 
2.12 γ-32P ATP Phosphate incorporation 
Tau protein was phosphorylated as detailed in (191). Briefly, tau was phosphorylated 
with 2 μM ATP plus 3.125 µCi [γ-32P] labeled ATP (Perkin-Elmer).  Samples were 
filtered and washed to remove unincorporated γ-32P, then counted in a liquid 
scintillation counter (Packard 1600TR) (191).  
 
2.13 Binding of unphosphorylated tau to microtubules 
The binding of tau to microtubules was performed using the commercially available 
Microtubule Binding Protein Assay Kit (Cytoskeleton, Inc.) using the manufacturer's 
protocol.  Varying concentrations of tau (0 μM–10 μM) were mixed with a constant 
concentration of paclitaxel stabilized microtubules at a final concentration of 1.6 μM 
tubulin dimers and 20 μM paclitaxel in a 50 µL reaction with the general tubulin 
buffer (GTB) supplied with the kit (80 mM PIPES, pH 7.0, 2 mM MgCl2, 0.5 mM 
EGTA).  Samples were incubated at room temperature for 30 minutes, and 





Beckman TLA 100 rotor at 100,000 × g for 5 minutes to sediment both tau-free 
microtubules and tau-bound microtubules.  Pellets were resuspended in 1× SDS 
sample buffer (0.0625 M Tris, 2% SDS, 10% glycerol, 5% β-mercaptoethanol) and 
tau bound to microtubules were separated from tubulin by electrophoresis.  SDS-
polyacrylamide gels were scanned with a Hewlett Packard Scanjet 7400 C and the 
density of the tau contained in the pellet (bound tau) was determined using Adobe 
Photoshop and a tau standard curve on the same SDS-polyacrylamide gel.  Isoforms 
0N3R, 0N4R, 1N3R, and tubulin have similar electrophoretic mobility.  In order to 
distinguish tau from tubulin bands, the protein were transferred to PVDF by standard 
western blot techniques and probed with tau 46.1 primary antibody (gift from Lester I. 
Binder) and goat anti-mouse horseradish peroxidase conjugated secondary (Pierce).  
Amersham ECL Plus Western Blotting Detection System was used to detect the 
secondary antibody (GE Healthcare).  The PVDF membrane was visualized using the 
Kodak Image Station 4000R (Eastman Kodak Co.).  Band intensities were determined 
by the histogram function of Adobe Photoshop.  The amount of free tau left in 
solution was determined by subtracting the amount of tau in the bound fraction from 
the total amount of tau added to the reaction and normalized to the band intensity of 
tubulin.  The concentrations of tau free in solution versus bound tau were plotted in 











2.14 Binding of phosphorylated tau to microtubules 
Individual tau isoform phosphorylation reactions (92 µL), containing 18.11 μM final 
concentration of tau, 0.018 U GSK-3β per pmol of tau in buffer (40 mM HEPES, pH 
7.64, 5 mM EGTA, 3 mM MgCl2, and 2 mM ATP) were incubated for 20 hours at 
30 °C to achieve maximal phosphate incorporation (191).  Microtubule binding 
reactions were subjected to ultracentrifugation as described above and separated by 
SDS-polyacrylamide gel electrophoresis.  0N3R, 0N4R, and 1N3R were transferred 
to PVDF by standard western blotting techniques as described above, and PVDF blots 
were treated with shrimp alkaline phosphatase (Roche) before blocking, to remove 
the phosphate groups that interfere with tau 46.1 antibody binding.  Images of gels 
and blots were collected and processed by methods described above, except that due 
to the large concentration of tubulin we were unable to normalize the data to the 
corresponding band.  Due to variable data, 5 outliers were excluded from calculations 
based upon being more than twice as different as the corresponding trials.  These 
points are 0N4Rp trial 3 1 μM and 2 μM, 1N3Rp trial 1 8 μM and trial 2 10 μM, and 
2N3Rp trial 2 10 μM.  
 
2.15 Hsp70 expression and purification 
Hsp70 (HSPA1A) (Open Biosystems) was cloned into a pET28b vector (Novagen) 
with an N-terminal histidine tag and purified by nickel affinity chromatography using 
Chelating Sepharose Fast Flow (GE Healthcare) followed by size exclusion 





The concentration of the protein from pooled Superdex 200 fractions was determined 
by a commercially available BCA kit (Pierce).  Purity was determined by running 
sub-microgram amounts on SDS-PAGE gels and staining with coomassie blue. 
 
2.16 ARA, Congo red, or Heparin induced tau polymerization with 
Hsp70 
ARA (Cayman Chemicals 90010.1, in ethanol) at a final concentration of 150 µM 
(the concentration of ethanol carrier was kept constant at 3.75% for all reactions), and 
individual tau isoforms at a final protein concentration of 4 μM, BSA at 0.25 µM (to 
prevent filament clumping at higher temperatures) were incubated with 
polymerization buffer containing (10 mM Hepes, pH 7.64, 100 mM NaCl, 0.1 mM 
EDTA and 5 mM DTT) for 18 hours at 37 °C (51, 150, 191-194).  Congo Red (CR) 
(Sigma C6277, dissolved in water) at a final concentration of 10 µM, and 2N4R tau at 
a final protein concentration of 2 µM were incubated in polymerization buffer 
containing (100 mM NaCl, 10 mM Hepes, pH 7.64, and 5 mM DTT) for 18 hours at 
37 oC (195).  Heparin (Sigma H4784 Lot#116K1130, estimated molecular weight 
between 6-30 kDa dissolved in water) at 6 µg/ml and 2N4R tau at a final protein 
concentration of 2 μM were incubated in polymerization buffer containing (30 mM 
Hepes, pH 7.64, 17.74 mM NaCl and 5 mM DTT)  for 18 hours at 37 °C (51, 150).  
Reactions with ARA, CR or Heparin were incubated with varying concentrations (0-2 






2.17 LLS kinetics with Hsp70 and 2N4R tau 
4 µM 2N4R tau with 150 µM ARA was incubated in polymerization buffer 
containing 100 mM NaCl, 10 mM Hepes pH 7.64, and 5 mM DTT and varying 
concentrations of Hsp70 (0-0.5 µM).  Reactions were read using LLS for 6 hours and 















































Where Y equals the LLS intensity (arbitrary units), a is the maximum amount of 
polymerization (arbitrary units), k1 is the inverse of the induction period (the time 
until a signal is observed) (minutes-1), and k2 is proportional to the rate of 
polymerization (AU/min). 
 
2.18 ATP involvement in Hsp70 inhibition of ARA induced 2N4R tau 
polymerization 
4 μM 2N4R tau was incubated in polymerization buffer (100 mM NaCl, 10 mM 
Hepes pH 7.64, 5 mM EGTA, 5 mM DTT) with 150 μM ARA, 0.25 μM BSA and 
varying conditions of ATP (0 mM- 2 mM), and Hsp70 (0 μM- 4 μM).  Reactions 






2.19 Addition of Hsp70 after 2N4R tau polymerization to determine if 
tau filaments can be disassembled 
4 µM 2N4R tau was polymerized in the presence of 150 µM ARA in polymerization 
buffer (100 mM NaCl, 10 mM Hepes pH 7.64, 5 mM EGTA, 5 mM DTT, 0.25 µM 
BSA) for 6 hours at 37 oC.  After polymerization, reactions were incubated with or 
with (1 µM Hsp70, 2 mM ATP, and 3 mM MgCl2) 18 hours at 37 oC.  EM grids of 
reactions after 6 hours and after 24 hours were analyzed by Image Pro Plus for length 
and distribution of tau filaments (see 2.21 for details). 
 
2.20 50% inhibition of tau polymerization values 
50% inhibition of tau polymerization was determined by normalizing data from LLS 
or ThS to 100% as the highest value of polymerization (Y-axis) and 0% as the lowest 
values of polymerization.  The equation for the line between the two points where 
50% (Y-axis) would lie was created for each trial.  The specific equation for each trial 
of each isoform was then used to find the concentration of Hsp70 (x-value) by 
inserting 50 as the y-value (%) and solving for x. 
 
2.21 Analysis of electron microscopy images with Image Pro Plus 
TEM images were analyzed for the number of filaments and the length of individual 
filaments per field using Image Pro Plus 6 (Media Cybernetics).  Electron dense 
material is visualized in the images as black objects on the grey background and 





Images were set to a threshold so that electron dense filamentous material was within 
the range, but any non-specific background material was not included.  The program 
also ignores any dense material that does not meet defined length and area criteria.  0 
µM 2N4R tau, 2 µM Hsp70 controls were used to determine background material, 
which is used as the criteria for quantitation.  Analysis showed the average length of 
the electron dense material to be 25 nm and 15 nm wide.  Objects that were longer 
than 25 nm, and having an area greater than 375 nm2 (25 nm long and 15 nm wide 
(average filament width)) were counted, measured for length, and exported to 
Microsoft Excel.  Objects from each image were sorted into three categories.  Objects 
greater than and equal to 25 nm and less than 50 nm are considered “small”, objects 
greater than and equal to 50 nm and less than 100 nm are considered “medium” and 
objects greater than and equal to 100 nm are considered “large”.  These cutoffs were 
chosen based upon previous observations that most tau filaments are between 50 nm 
and 100 nm.  Data for approximately 0%, 50%, and 100% inhibition of tau 
polymerization by Hsp70 was plotted as the mean ± SEM of 5 images per reaction. 
 
2.22 Microtubule assembly assay and data fitting 
Microtubule assembly assays were performed using a commercially available DAPI 
fluorescence based porcine tubulin polymerization assay kit BK011P (Cytoskeleton), 
using the manufacturer’s protocol for enhancers of tubulin polymerization (no 
glycerol).  Every reaction used the same preparation of tubulin, Hsp70 and tau 





oC and were read every minute for an hour using a Molecular Devices Flexstation II 
plate reader with an excitation of 355 nm and an emission of 455 nm.  Tubulin 
polymerization reactions containing taxol alone, Hsp70 alone, and polymerization 
buffer alone were used as controls.  Data for microtubule assembly reactions was 
normalized to taxol assembled microtubule reactions that were run at the same time to 
adjust for any variability in tubulin polymerization.  Normalized data was fit to the 







where Y is the relative fluorescence level, a is the maximum amount of fluorescence, 
x is time, b is 1/kapp and kapp is proportional to the rate of polymerization, and c is the 
point of greatest increase in Y.  Lag time to significant polymerization (calculated by 
c-b), kapp and max were determined from the equation for 3 separate trials with or 





Chapter 3- The Effects of Inducer Molecules and Post-translational 
Modifications on Tau Polymerization 
 
Part 1.  ARA and heparin induced 2N4R Tau Polymerization In 
Vitro  
 
Work on in vitro modeling of arachidonic acid and heparin induced 2N4R tau polymerization was a 
collaborative effort that I contributed to.  It is presented here as data that is not entirely my own.  
Figures are reproduced from: Carlson SW, Branden M, Voss K, Sun Q, Rankin CA, and Gamblin TC, 





Amyloid polymerization in general is thought to follow a nucleation-elongation 
mechanism.  This means that the protein forming amyloid must first form a nucleus 
that acts as a source for other monomers to add and elongate.  Tau protein is thought 
to follow a similar mechanism.  It has been shown that wild-type tau incubated at 
high concentration of protein and long incubation times fails to polymerize in vitro 
(198).  Therefore, in order to research tau polymerization we must add inducer 
molecules that reduce the energetic barrier for polymerization to proceed.  This 
energetic barrier for nucleation depends on the hydrophobicity and β-sheet formation 
properties of the protein (199).  The energic barrier is defined as the critical 
concentration of polymerization, below which elongation does not proceed.  The 





any.  However, addition of ARA or heparin will cause tau to form filaments that are 
structurally similar (formation of cross β-sheet structure) to those isolated from tau 
inclusions from the brains of AD patients (200).  Other similarities between 
aggregated tau from the brains of AD patients and aggregated tau from in vitro 
reactions include similar densities, widths of ~15 nm, ThS positive and Alz50 
antibody reactivity (201, 202).  The work presented here describes a different 
mechanism upon the addition of inducer molecules to alter tau polymerization from 
the standard nucleation-elongation mechanism to one that depends on the 
concentration of the inducer molecule that allosterically regulates polymerization.  
This means that at low inducer levels tau polymerization is low, but increases upon 
addition of more inducer.  After an optimal ratio of inducer to protein, polymerization 
decreases upon addition of more inducer, indicating the inducer inhibits the formation 
of filaments.  The inducer also lowers the critical concentration of polymerization to 
nearly zero; meaning formation of nuclei is spontaneous.  Here we describe a role 
ARA and heparin play in formation of 2N4R tau filaments in vitro. 
 
3.1.2 Results 
3.1.2.1 ARA and heparin induced formation of tau filaments 
The formation of tau aggregates in neurons correlates with cognitive impairment, 
however, the mechanism of formation is not known.  Likewise, modifications to tau 
could alter how polymerization proceeds.  As a first step to understand aggregation, 





examined tau polymerization using two main inducer molecules.  ARA is a poly-
unsaturated fatty acid with one negative charged group at one terminus and heparin 
sulfate is a glycosaminoglycan that has multiple negative charges along the entire 
molecule.  In the absence of inducer, tau fails to polymerize even when tau 
concentrations are increased (Figure 3.1A, B).  In the presence of either ARA (75 µM) 
(Figure 3.1C) or heparin (0.376 µM) (Figure 3.1E) tau polymerization can be detected 
by both LLS and ThS.  Polymerization of tau with ARA and heparin also increases as 
the concentration of tau increases (Figure 3.1C, E).  There is an obvious difference in 
the morphology of tau filaments upon polymerization.  ARA mediated tau 
polymerization produces more numerous, but shorter filaments than heparin (Figure 
3.1D, F).  The pathological or toxic consequences of the morphologies are not known, 
but the morphologies are similar, as they represent straight filaments seen in AD 
extracted insoluble tau.   
 
3.1.2.2 Polymerization of 2N4R tau with ARA and heparin produces a 
biphasic dose response  
When 2N4R tau at various concentrations (0-4 µM) was incubated with various 
concentrations of ARA (0-300 µM) (Figure 3.2A) or heparin (0-2 µM) (Figure 3.2B), 
and examined by ThS, a biphasic dose response curve resulted.  This biphasic 
response indicates that at low inducer to protein levels the concentration of inducer 
limits the amount of elongation that can proceed.  We know this because the addition 







Figure 3.1 Nonlinearity of tau polymerization with regulatory molecules.  Tau 
protein at various concentrations (x-axis) was incubated alone (A and B), with 75 µM 
ARA (C and D), and with 0.376 µM  heparin (E and F) for approximately 16 h, and 
the final extent of polymerization was determined by LLS (●, left y-axis) and ThS 
fluorescence (○, right y-axis).  The presence or absence of filaments was confirmed 
by EM (B, D, and F).  Note that the scales of the x-axes and y-axes are different for 
the different conditions because virtually no polymerization was observed without 
regulatory molecules, and ARA gave a much stronger signal than did heparin under 
these conditions.  Data in A represent a single experiment.  C and E show an average 







Figure 3.2 Variation of regulatory molecule concentrations in tau polymerization 
reactions.  Tau polymerization reactions at 1 (□), 2 ( ▲), and 4 (▼) µM protein 
concentration were mixed with various concentrations (x-axis) of (A) ARA or (B) 
heparin and incubated for approximately 20 h. ThS was added at a final concentration 
of 20 µM, and the amount of resulting fluorescence was determined.  The error bars 





inducer to protein levels in inhibited by the inducer concentration.  We know this 
because the addition of more inducer results in less polymerization.  In between these 
two parts of the curve lies an optimal amount of inducer to protein at which we 
achieve the maximum amount of polymerization.  The optimal ratio of inducer for 
ARA: tau was 37.5:1, while for heparin the ratio was 0.188:1.  This difference in the 
optimal ratio indicates that inducer mediated polymerization may follow different 
mechanisms based upon the inducer used.  
 
The filament morphology of ARA-mediated tau polymerization changes at different 
ratios (Figure 3.3).  At an inhibitory ratio, tau filaments are short (<50nm), similar to 
what has been described as a potential toxic species of tau isolated from AD neurons 
(Figure 3.3A, B).  As the ratio shifts to the optimal ratio, longer filaments begin to 
form (Figure 3.3C).  Increasing the protein concentration, even more, to shift the ratio 
to a limiting ratio, results in a shift to even longer filaments (Figure 3.3D, E).  
Knowing the optimal ratio is important because if reactions are carried out at lower or 
higher ratios, the results are skewed to what looks like longer or shorter filaments, 
and more or less polymerization than another form of tau that may have a different 
optimal ratio.  Likewise, in a cell, having a small amount of heparin can polymerize 
tau, while higher concentrations of ARA would be required for polymerization to 
proceed.  This may indicate that there is interplay of inducers, where small amounts 
of heparin could initiate formation, but then be inhibited by increasing concentrations 






Figure 3.3 Length distribution of tau filaments changes as a function of protein 
concentration.  Representative electron micrographs taken at 20,000x (the bar in E 
represents 500 nm and is applicable to all images) for polymerization reactions in the 
presence of 75 µM ARA following approximately 16 h of polymerization are shown 
for several different concentrations of tau: (A) 0.5 µM; (B) 1.0 µM; (C) 2.0 µM; (D) 
3.0 µM; and (E) 4.0 µM.  The average mass frequency distributions are shown for 
each of these concentrations and are plotted as the percent of the total mass that one 





 promoted filament formation, ARA could take over as an inducer for polymerization. 
 
3.1.2.3 2N4R polymerization kinetics with ARA 
By changing the concentrations of inducer at a specific tau concentration, we observe 
changes in the kinetics of polymerization and filament morphology.  Polymerization 
reactions with ARA (Figure 3.4) were measured over time using ThS fluorescence at 
a limiting, optimal and inhibitory ratio.  Data in Figure 3.4A, C, and D was fit to a 












 KteYY 1max . 
Where increases over time t, in polymer from zero to Ymax, have a rate constant K.  
The half time of the reaction to reach equilibrium, t1/2, is defined as 0.69/K.  With 
ARA, there was no change in the t1/2 or K, for a given ratio, with increasing protein 
concentration (Figure 3.4E, F).  Between ratios, the t1/2 decreased significantly for the 
inhibitory ratio, but was not significantly affected for the limiting ratio as compared 
to the optimal ratio (Figure 3.4E).  The rate of polymerization, K, was unchanged 
between the optimal and limiting ratios, but significantly higher in the inhibitory ratio 
(Figure 3.4F).  In order to determine the size of the nucleus for polymerization, data 
for the optimal ratio was also fit to a nucleation equation:   
( ) ( )∞−+− −= 11111 TTTkKdt
dC n





 Where C  is the polymer addition sites concentration, 1T  is tau monomer 
concentration, ∞1T is the critical concentration, 
+k is the rate constant for elongation, 
1−nK is the association constant for nuclei formation, and n  is the size of the nucleus.  
By inserting many combinations of different values for 1−nK , 
+k , and n  we can fit 
the data at a particular protein concentration, but there is only one combination that 
allows all protein concentrations to be fit at the same time (190).  The only nucleus 
size that fit all protein concentrations was zero, indicating that addition of ARA 
reduces the nucleation (critical concentration) to zero (Figure 3.4B)   When combined 
with EM data, this kinetics data suggests that the inhibitory ratio blocks elongation of 
filaments by creating a burst of nucleation of tau, in which not enough tau monomer 
remains to be incorporated into filaments. 
 
3.1.2.4 2N4R polymerization kinetics with heparin 
The kinetics of formation in the presence of heparin was also measured with 
increasing tau concentrations at optimal, limiting and inhibitory ratios (Figure 3.5A-
C).  Data was fit to the one phase exponential association equation described above.  
Again, at a given ratio, the t1/2 and K were similar for all protein concentrations.  The 
optimal and limiting ratios had a similar t1/2, but the inhibitory ratio had a 







Figure 3.4 Kinetics of ARA induction of tau polymerization.  The kinetics of tau 
polymerization was followed with ThS fluorescence at a constant molar ratio of (A) 
37.5:1 (Optimal), (B) 37.5:1 (Optimal), (C) 18.75:1 (Limiting), and (D) 75:1 
(Inhibitory) at 0.5, 1, 2, 3, and 4 µM tau ((), individually labeled on graph) .  The 
data in A, C, and D were fit to a single phase exponential association equation to 
obtain the values for (E) t1/2 and (F) K.  The data in E and F are the average values ± 
SEM for all polymerization reactions that had final polymerization values of more 
than 10 ThS units.  The asterisks denote values that were significantly different from 
optimal conditions using a t-test (p<0.01)  The data in (B) was converted to molar 
concentrations of tau assuming the ThS fluorescence at steady state was equal to the 
polymer concentration (calculated by subtracting the critical concentration from the 
total concentration) and fit to equations derived for the kinetics of actin nucleation 
and polymerization (190) using n = 0, nucKk
+ = 5x10-4 s-2M-4 (---), n = 1, nucKk
+ = 
1.2x102 s-2M-4 (∙∙∙), and n = 2, nucKk






Figure 3.5 Kinetics of heparin induction of tau polymerization.  The kinetics of 
tau polymerization was followed with ThS fluorescence at a constant molar ratio of 
(A) 0.188:1, (B) 0.094:1, and (C) 0.376:1 at 0.5, 1, 1.5, 2, 3, and 4 µM tau ((),
individually labeled on graph).  The data were fit to a single phase exponential 
association equation to obtain the values for (D) t1/2 and (E) K.  The data in D and E 
are the average values ± SEM for all polymerization reactions that had final 
polymerization values of more than 10 ThS units.  The asterisks denote values that 
were significantly different from those at optimal conditions using a t-test (* = p<0.05, 





The rate of formation was significantly affected for the limiting ratio, and affected 
even greater for the inhibitory ratio as compared to the optimal ratio (Figure 3.5E).  
The rate of formation for heparin was slower than that observed for ARA, and in 
conjunction with EM data which shows fewer but longer filaments, indicates heparin 
does not nucleate tau as well. 
 
3.1.3 Conclusions 
Understanding the mechanisms by which tau polymerization proceeds provides 
insight into how progression of tauopathies can occur.  The work presented in 
Chapter 3 Part I has provided insight into these mechanisms for full length wild type 
tau, under the control of two distinct inducers of polymerization.  Our tau 
polymerization  results agree with previous results (203) and is enhanced in the 
presence of both inducers, as compared to no inducer which fails to polymerize even 
at high protein concentrations and long incubation times.  The inducers lower the 
critical concentration for polymerization to near zero, indicating tau in the presence of 
inducers does not follow the traditional nucleation-elongation mechanism.  This is 
confirmed with our kinetics analysis of ARA and heparin induced polymerization, 
where the lag phase characteristic of nucleation is not present.  These inducers also 
act as allosteric regulators of tau polymerization, where at low concentrations of 
inducer, tau cannot polymerize as effectively as when more inducer is added.  
Eventually, an optimal ratio is reached, which is different for the two inducers used, 





occurs by creating many short filaments that indicates a burst in nucleation that 
removes enough monomer from the solution that elongation cannot occur.  This could 
have consequences for disease in that local concentrations of ARA could create a 
burst in short tau polymer that provides a source for later elongation to occur.  This 
research has provided a foundation for examining tau polymerization in vitro.  
However, tau exists in neurons as six alternatively spliced isoforms that can be 
phosphorylated.  In Chapter 3 Part II, we will examine differences in wild-type and 






Chapter 3 Part II- GSK-3β Phosphorylation Differentially Affects 
Tau Isoform Dysfunction and Function  
Voss and Gamblin, Mol. Neurodegen., 2009, 4:18, http://www.molecularneurodegeneration.com/content/4/1/18 
 
3.2.1 Introduction 
Tauopathies, such as Alzheimer's disease (AD), are characterized by the abnormal 
aggregation of a hyperphosphorylated microtubule associated protein, tau.  The 
aggregation and phosphorylation of tau correlates with neurodegenerative changes in 
these diseases (reviewed in (204)). It is therefore generally believed that aggregation 
and phosphorylation changes are causative factors in the etiology of tauopathies.  One 
complicating factor to these observations is that tau mRNA is alternatively spiced to 
give rise to six protein isoforms.  The isoforms are generated by splicing of exons 2, 3 
and 10, which encodes for microtubule binding repeat 2, giving rise to isoforms with 
three microtubule binding repeats (3R) or four (4R) (5).  The levels of 3R and 4R tau 
do not differ between normal and AD brains, but in both cases, the levels of 
alternatively spliced N-terminal exons differ.  Isoforms with only exon 2 are the most 
abundant, followed by isoforms without N-terminal exons and isoforms with both 
exons 2 and 3 are the least abundant (11).  In other tauopathies, the ratio of 3R 
isoforms to 4R isoforms can be altered (reviewed in (30)). For example, progressive 
supranuclear palsy (PSP) can be accompanied by increases in 4R tau, while Pick's 
Disease is often characterized by an increased amount of 3R isoforms (reviewed in 





or hinder splicing of exon 10, but have no effect on the protein sequence (reviewed in 
(205)). The above observations suggest that a shift in isoform expression may 
contribute to neurodegenerative changes in tauopathies.  However, the individual 
contributions of tau isoforms to the neurodegenerative process are not well 
understood.  One possibility is that the inherent differences between isoforms are 
sufficient to cause neurodegenerative changes when their relative levels are altered. 
 
Tau polymerization into filaments similar to those observed in neurodegenerative 
diseases can be modeled in vitro by the addition of inducer molecules such as 
arachidonic acid (ARA) and heparin (reviewed in (203)) in a complicated fashion (see 
Chapter 3 Part I) (51). It is currently unknown whether different isoforms share ARA 
and heparin-induced polymerization profiles similar to 2N4R tau.  
 
In addition to being abnormally polymerized, tau has been shown to be 
hyperphosphorylated in AD pathology.  "Hyperphosphorylated" is a loosely defined 
term used to describe abnormally or inappropriately phosphorylated tau in AD.  
Although there is not a strict definition, some properties of hyperphosphorylated tau 
include altered electrophoretic mobility, conformational changes, increased levels of 
phosphate incorporation, and site-specific inappropriate phosphorylation (206-208).  
While it is not known how hyperphosphorylated tau is generated, glycogen synthase 
kinase-3β (GSK-3β) is widely believed to play a role in this process (reviewed in 





determined by mass spectrometry, and phosphorylation site-specific antibodies (191, 
193, 209, 210).  In vivo, treatment of transgenic mouse models of tau-induced 
neurodegeneration with lithium chloride, an inhibitor of GSK-3β, reduces both tau 
phosphorylation and resulting tau pathology (211), (212).  Phosphorylation of 2N4R 
tau in vivo by GSK-3β has reduced affinity for microtubules (213) and 
phosphorylation of 0N3R tau in vitro by GSK-3β shows mild changes in affinity of 
tau for microtubules (214). Recombinant 2N4R tau phosphorylated by GSK-3β, upon 
polymerization with an inducer, forms structures that resemble neurofibrillary tangles 
in vitro (51, 193).  However, it is not known how GSK-3β phosphorylation affects the 
other tau isoforms, and given their differences in primary structure, it is possible that 
phosphorylation will have differential impacts on their function.  We have therefore 
characterized the polymerization and microtubule binding properties for each isoform, 
and the effect that phosphorylation by GSK-3β has on these properties.  We have 
found that there are fundamental differences in the functions of 3R and 4R isoforms.  
These differences are largely determined by the presence or absence of exon 10, with 
some contributions from exons 2 and 3.  Phosphorylation by GSK-3β modulates the 
function of tau, but only mildly.  The data suggest that phosphorylation alters all 
isoforms to approximately the same degree.  These results suggest that the inherent 
properties of the isoforms are primarily responsible for their variable involvement in 








3.2.2.1 Tau isoforms 
The tau transcript is alternatively spliced in humans to form six isoforms.  These 
isoforms (0N3R, 0N4R, 1N3R, 1N4R, 2N3R, 2N4R) are classified by the presence or 
absence of N-terminal exons 2, 3, and C-terminal exon 10 (containing microtubule 
binding repeat 2) (see Chapter 1).  We expressed and purified each recombinant 
isoform from E. coli (Figure 3.6).  The isoform identity was confirmed by molecular 
weight determination on coomassie stained-sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) as compared to expected values in the literature 
(188, 208). 
 
3.2.2.2 Isoform differences in ARA induced polymerization 
Because the primary sequences of the tau isoforms are different, the various 
combinations of exons could influence their interactions with inducer molecules or 
cause conformational changes affecting tau-tau interactions during the polymerization 
process.  The polymerization characteristics of each isoform was determined by 
incubating 2 μM protein with a range of ARA concentrations (0–150 μM) and 
monitoring the extent of polymerization with right angle laser light scattering (LLS, 
Figure 3.7A) and thioflavine S fluorescence (ThS, Figure 3.7A).  We determined that 
above 100 μM ARA, the results were highly variable and not easily reproducible 
(data not shown).  This is consistent with previously published results showing high 






Figure 3.6 Variation between tau isoforms.  The six tau isoforms differ in the 
presence or absence of N-terminal exons 2 and 3 and the presence or absence of exon 
10 in the microtubule binding domain.  Each lane is labeled with the name of the 
isoform analyzed.  Each isoform migrates a distinct distance on a Coomassie stained 






The isoforms followed the same general trend of increased amounts of 
polymerization with increased inducer concentrations.  4R tau isoforms (containing 
exon 10) polymerized to a greater extent than 3R isoforms (Figure 3.7A, B), 
indicating that the additional microtubule binding repeat enhances tau polymerization.  
The resulting filaments from the polymerization reactions above were viewed by 
transmission electron microscopy (TEM, Figure 3.7C–H).  At equivalent ARA 
concentrations (75 μM), the greatest amount of filament formation was observed with 
the 1N4R and 2N4R isoforms (Figure 3.7G, H).  Fewer filaments were observed for 
1N3R and 2N3R (Figure 3.7D, E).  Isoforms lacking both N-terminal exons (0N3R 
and 0N4R, Figure 3.7C, F) tended to form very small filaments (< 50 nm), as has 
been described previously (188), but large aggregates of longer filaments were also 
observed, albeit infrequently (Figure 3.8). We, and others, have found that while 
aggregates of tau polymer can be detected by LLS and ThS fluorescence, these 
aggregates may not be uniformly distributed on a TEM grid, resulting in the user not 
being able to see these aggregates unless they scan the entire grid. 
 
3.2.2.3 Isoform differences in heparin induced polymerization 
Because it is known that some isoforms do not polymerize equally in the presence of 
heparin (215), the polymerization characteristics for all six isoforms were determined 
under conditions of low ionic strength (216, 217). The isoforms (2 μM) were 
incubated in the presence of various concentrations (0–0.024 mg/ml) of heparin and 






Figure 3.7 ARA induction of tau isoform polymerization.  2 μM tau isoforms were 
incubated with various ARA concentrations (0 μM to 100 μM) for 18 hrs.  
Polymerization was measured by (A) LLS or (B) ThS fluorescence.  Symbols 
correspond as follows: (open square) 0N3R, (closed square) 0N4R, (open triangle) 
1N3R, (closed triangle) 1N4R, (open circle) 2N3R, (closed circle) 2N4R, and (closed 
diamond) assembly incompetent protein (AIP (I277, 308P)).  Data is in arbitrary units 
and represents an average of 3 trials ± SEM.  After 18 hours, ARA induced 
polymerization reactions were visualized by TEM at 20,000x magnification.  Images 
are as follows: (C) 0N3R, (D) 1N3R, (E) 2N3R, (F) 0N4R, (G) 1N4R, and (H) 2N4R.  
Each isoform image is representative of polymerized material at 75 μM ARA.  Scale 






Figure 3.8 Polymerization of 0N3R and 0N4R isoforms with 75 μM ARA into 
larger aggregates is seen, but infrequent.  0N3R (A, C, E) and 0N4R (B, D, F) 
isoforms exhibit filament elongation and clustering under nonphosphorylated 
conditions.  Reactions from Figure 3.7 were visualized by TEM at 20,000× 
magnification.  Each image is from a different trial, and was found to occur at about 







Figure 3.9 Heparin induction of tau isoform polymerization.  2 μM tau isoforms 
were mixed with various heparin concentrations (0 mg/ml to 0.024 mg/ml) and 
incubated 18 hrs.  Polymerization was measured by (A) LLS or (B) ThS fluorescence.  
Symbols correspond as follows: (open square) 0N3R, (closed square) 0N4R, (open 
triangle) 1N3R, (closed triangle) 1N4R, (open circle) 2N3R, (closed circle) 2N4R.  
Data is in arbitrary units and represents an average of 3 trials ± SEM except for 2N4R 
with 0.006 and 0.018 mg/ml heparin, 1N4R with 0.024 mg/ml heparin, and 0N4R 
with 0.018 mg/ml heparin which were 2 trials.  After 18 hours, heparin induced 
polymerization reactions were visualized by TEM at 20,000× magnification.  Images 
are as follows: (C) 0N3R, (D) 1N3R, (E) 2N3R, (F) 0N4R, (G) 1N4R, and (H) 2N4R.  
Each isoform image is representative of polymerized material at 0.006 mg/ml heparin.  





 Polymerization was detected by both methods for the 4R isoforms, and the dose-
response curve was biphasic, indicating an optimal inducer concentration for 
polymerization.  2N4R required a lower concentration of heparin for optimal 
polymerization than 0N4R and 1N4R.  Under these heparin induction conditions, the 
3R isoforms failed to polymerize to detectable levels above background (Figure 3.9A 
and 3.9B).  4R isoforms (Figure 3.9F–H) were induced to form long filaments, but 3R 
isoforms (Figure 3.9C–E) did not polymerize into any observable filaments by TEM.  
 
3.2.2.4 Tau isoforms are phosphorylated by GSK-3β 
All six tau isoforms are abnormally hyperphosphorylated in neurofibrillary tangles 
found in AD pathology.  However, the functional consequences of this 
phosphorylation are unknown.  Previous studies have found that tau phosphorylation, 
in general, reduces its binding to microtubules (37). Likewise, ARA induced 
filaments of GSK-3β phosphorylated 2N4R tau coalesce into "neurofibrillary tangle-
like" structures (51, 193).  To determine whether GSK-3β exerted similar effects on 
other tau isoforms, we examined the effects of GSK-3β phosphorylation by 
measuring the extent of phosphorylation; microtubule binding and ARA induced 
polymerization.  GSK-3β phosphorylation of 2N4R tau results in an upward shift in 
mobility on SDS-PAGE gels (51). The effects of GSK-3β phosphorylation on the 
electrophoretic mobility of the other isoforms was examined by visualizing 
phosphorylation reactions of each isoform by SDS-PAGE (Figure 3.10A).  All 






Figure 3.10 GSK-3β phosphorylation of tau isoforms visualized by changes in gel 
mobility and phosphate incorporation.  (A) The migration of GSK-3β 
phosphorylated tau isoforms (p) was compared to unphosphorylated isoforms (up) by 
Coomassie-stained SDS-PAGE.  The isoforms are labeled above their respective 
lanes.  2N4R was analyzed on a separate gel and then aligned by its relative migration 
to molecular weight standards.  (B) γ-32P ATP was added to the phosphorylation 
reaction overnight and moles of phosphate per mole of tau was calculated by 






its non-phosphorylated standard (Figure 3.10B).  The quantity of the shifted tau band 
was unequal for the different isoforms, despite equivalent conditions for 
phosphorylation.  One potential explanation for the differences in quantity could be 
that the degree of phosphate incorporation is not equal for all isoforms.  Therefore, 
the levels of phosphorylation by GSK-3β were determined directly for each isoform 
by using γ-32P ATP.  An average of approximately 1 mole phosphate was 
incorporated per mole of tau for each isoform (Figure 3.10B).  Only 0N3R showed 
lower phosphate incorporation, but due to the variability in the reactions, this 
difference did not reach statistically significant levels.  Therefore, the difference in 
electrophoretic mobility between phosphorylated and non-phosphorylated tau, is not 
likely due to significant changes in phosphate incorporation, but rather could be due 
to similar levels of phosphorylation resulting in different levels of SDS-resistant 
conformational changes in the isoforms.  Alternatively, the difference in the quantity 
could be a result of experimental variability of phosphorylation by GSK-3β. 
 
3.2.2.5 Microtubule binding of tau isoforms changes with 
phosphorylation by GSK-3β 
Tau is a microtubule-associated protein that, when phosphorylated at specific sites in 
the microtubule binding regions, such as at site S262 by p110MARK (microtubule 
affinity regulating kinase), promotes strong disassociation (~10×) from microtubules 
(218), while phosphorylation outside of the microtubule binding regions (such as by 





We therefore determined the effects of phosphorylation by GSK-3β on the 
microtubule binding affinities of each isoform, using unphosphorylated protein as a 
control (Figure 3.11A–F).  Unphosphorylated 4R isoforms bound more tightly than 
the unphosphorylated 3R isoforms (Figure 3.11G), which is consistent with 
previously published results (26).  Upon phosphorylation, the largest decrease in 
microtubule affinities occurred in 1N isoforms (~3×) (Figure 3.11G); indicating 
GSK-3β phosphorylates 1N isoforms at sites that mildly influence microtubule 
binding.  The average Kd of phosphorylated 0N3R, 0N4R, and 2N4R isoforms was 
higher than the corresponding unphosphorylated Kd, however, these changes did not 
reach statistically significant levels (Figure 3.11G).  2N3R showed an increase in 
affinity for microtubules upon GSK-3β phosphorylation.  These data indicate that 
phosphorylation by GSK-3β has mild effects on the microtubule binding of tau 
isoforms, which is consistent with phosphorylation at the proline rich region or other 
regions only mildly involved with microtubule binding. 
 
3.2.2.6 Phosphorylation of tau isoforms changes filament 
polymerization levels 
To determine how phosphorylation affects polymerization with ARA, all six isoforms 
were phosphorylated prior to the induction of polymerization.  Heparin was not used 
because it failed to induce polymerization in non-phosphorylated 3R isoforms (see 






Figure 3.11 Changes in microtubule binding of tau isoforms when 
phosphorylated with GSK-3β.  Microtubule binding reactions were performed at 
various concentrations of tau (0 μM to 10 μM) and bound vs. free tau (in μM) for 
both unphosphorylated (black circle) and phosphorylated (red circle) was plotted (A-
F).  Three separate trials are plotted together to demonstrate the variability in the 
reactions.  The data were fit to a nonlinear single site binding equation for 
unphosphorylated (black solid line) and phosphorylated (red solid line) tau isoforms 
(A-F).  The 95% confidence intervals of the fits are drawn as dashed lines.  Outliers 
existed for phosphorylated samples, are shown as red open boxes, and were excluded 
from calculations.  (G) The dissociation constant (Kd) (in μM) was determined for 
unphosphorylated (white bars) and phosphorylated (red bars) isoforms by Kd = the 






measured by LLS and ThS fluorescence (Figure 3.12).  Non-phosphorylated and 
phosphorylated assembly incompetent tau (AIP, I277/308P) was used to correct for 
background scattering as previously described (219).  2N3R (Figure 3.12A) and 
1N3R (Figure 3.12C) had relatively unchanged ThS values, but 2N3R had decreased 
LLS upon phosphorylation, while 1N3R had increased LLS.  The phosphorylated 
2N4R and 1N4R isoforms polymerized less than their unphosphorylated counterparts 
as measured by both LLS and ThS. Phosphorylated 0N3R had increases in both LLS 
and ThS, while 0N4R had no change in LLS, and decreased ThS.  The data indicate 
that phosphorylation does not influence the polymerization of isoforms equally, but 
these changes are mild in comparison to differences between unphosphorylated 
isoforms. 
 
3.2.2.7 Phosphorylation of tau isoforms changes filament morphology 
Because LLS readings can be influenced by the size and length of the particles (220) 
and it is not clear to which molecular species ThS binds (201, 221, 222), samples of 
phosphorylated tau isoform filaments were viewed by TEM to determine whether 
phosphorylation induces significant changes in filament morphology, as has been 
observed with 2N4R tau (51, 193). Representative micrographs of phosphorylated 
samples polymerized in the presence of 75 μM ARA indicate distinct morphological 
changes from unphosphorylated tau isoforms (Compare Figure 3.13 and Figure 3.7).  






Figure 3.12 Effect of phosphorylation on ARA induced tau isoform 
polymerization.  Each isoform (A) 2N3R, (B) 2N4R, (C) 1N3R, (D) 1N4R, (E) 
0N3R, and (F) 0N4R was polymerized with 75 μM ARA after phosphorylation by 
GSK-3β (+p) or without phosphorylation (-p).  Reactions were measured by LLS 
(black bars and left y-axis) and ThS fluorescence (open bars and right y-axis).  All 
LLS data is background subtracted with AIP for -p and AIPp for +p values 







Figure 3.13 TEM images of ARA induction of GSK-3β phosphorylated tau 
isoforms.  Images are as follows: (A) 0N3R, (B) 0N4R, (C) 1N3R, (D) 1N4R, (E) 
2N3R, and (F) 2N4R.  Images were recorded at a magnification of 20,000× (A-F) and 
are representative of polymerized material from 75 μM ARA induced-reactions 






relative length and number of filaments formed as compared to non-phosphorylated 
(Figure 3.7C, F).  Filaments formed from phosphorylated 1N3R and 1N4R (Figure 
3.13C, D) isoforms also appeared to be relatively more numerous, and longer than 
non-phosphorylated (Figure 3.7D, G), although these changes were less dramatic than 
for the 0N isoforms.  Phosphorylated 2N3R and 2N4R (Figure 3.13E, F) appeared to 
be relatively unchanged in the length and number of filaments (Figure 3.7E, H).  
Filaments from phosphorylated 0N3R, 1N4R, and 2N4R, had an increased tendency 
to cluster in close association to form "tangle-like" structures, similar to those seen 
previously with phosphorylated 2N4R induced with lower (25 μM) ARA 
concentrations (51, 193).  It is apparent that isoform and inducer concentration, as 




Many studies aimed at understanding the normal and abnormal functions of the 
microtubule-associated protein tau have focused on only one or two of its isoforms.  
However, all six isoforms of tau differ in their primary structure and therefore can 
potentially differ in their functions.  In fact it has been shown that significant 
differences exist between the microtubule binding and microtubule stabilizing 
capacities of isoforms with three microtubule binding repeats and those with four 
microtubule binding repeats (26, 223).  It has also been demonstrated that there are 





isoforms and four repeat isoforms (188, 215) and between isoforms with different 
numbers of N-terminal exons (188). We have recently demonstrated that the 
phosphorylation of the 2N4R isoform of tau by GSK-3β causes arachidonic acid 
induced filaments to coalesce into larger structures similar to those purified from 
Alzheimer's disease (51, 193).  Due to the potential differences between the 
characteristic functions of tau isoforms, we investigated the effects of GSK-3β 
phosphorylation on all six isoforms of tau.  As a necessary first step for this study, we 
established baseline parameters for the self-polymerization of non-phosphorylated tau 
isoforms.  This step was necessary because it is clear the type of inducer used and the 
conditions for polymerization have a large influence on the degree of polymerization 
of tau isoforms (51, 215-217).  Using arachidonic acid as an inducer for 
polymerization, we found several significant differences between the isoforms.  First, 
four repeat isoforms polymerized to a greater extent than three repeat isoforms.  
Secondly, removal of the two N-terminal exons (exons 2 and 3) increased the 
concentration of inducer required for maximal polymerization.  Lastly, the presence 
of exon 2 is sufficient to reduce the levels of inducer required for maximal 
polymerization because the addition of exon 3 to exon 2 containing isoforms does not 
further reduce inducer concentrations needed for maximal polymerization.  The 
structural involvement of exon 2 and 3 in filament formation is poorly understood, 
but could be related to the length of the N-terminus that is involved in regulating tau 
polymerization.  By altering the length of the N-terminal domain, tau may be able to 





The inducers may be able to play a role in mediating this difference in length by 
acting as a linker between the N-terminus and the MTBRs. 
 
A similar biphasic curve was obtained for the heparin induction of four repeat tau 
isoform polymerization.  However, in the presence of heparin, three repeat isoforms  
failed to polymerize to detectable levels.  The N-terminal exons also influenced the 
concentrations of inducer required to reach maximal polymerization.  The 2N4R 
isoform required less heparin inducer for maximal polymerization than 1N4R and 
0N4R.  The observation that three repeat isoforms essentially failed to polymerize in 
the presence of heparin was somewhat surprising because it has been shown that the 
heparin induced polymerization of 0N3R tau is actually enhanced as compared to 
2N4R tau (215). It should be noted that the heparin polymerization studies by the 
other lab were incubated at higher protein and inducer concentrations in solutions 
with greater ionic strength and for longer time periods than the current study.  Our 
conditions for polymerization are based on previously published conditions of low 
ionic strength, protein concentration and inducer concentration that result in efficient 
tau polymerization reaching apparent steady state in 24–48 hours (216, 217).  These 
results indicate that the local environment has a large impact on how individual tau 
isoforms self-polymerize, which could have an impact on isoform specific regulation 
of tau in the cell.  Our results and those of others strongly suggest that most isoforms 
of tau have distinct polymerization characteristics.  The local environment is a major 





respond equally to changes in environment.  GSK-3β has been shown to 
phosphorylate tau in transgenic mice and cause neurodegeneration (135), which can 
be abolished with lithium treatment to inhibit GSK-3β (211).  Based on these 
observations, we examined GSK-3β phosphorylation of tau isoforms. 
 
The levels of GSK-3β phosphorylation of the isoforms were similar at an average of 
approximately 1 mole of phosphate per mole of tau, although there was a large degree 
of variability in the amount of phosphate incorporation in repeated experiments.  On 
average, the 0N3R isoform was phosphorylated to a lesser degree than the other 
isoforms, but not at statistically significant levels.  One explanation for the low 
amount of phosphate incorporation could be that either the kinase or the γ-32P ATP 
did not work as effectively as it should, which could also explain the large variability 
among the three trials.  While the tau isoforms were not phosphorylated at ~8 moles 
of phosphate per mole of tau, similar to hyperphosphorylated tau found in tau 
pathologies, we do see a corresponding band shift, characteristic of 
hyperphosphorylated tau.  This could be explained by site specific phosphorylation, at 
T231, inducing an SDS-resistant conformational change.  Phosphorylation at T231 is 
recognized by the prolyl isomerase, Pin1, to reverse conformational and functional 
changes that would otherwise result in increased polymerization and decreased 
microtubule binding (224, 225).  Since previous results have shown T231 
phosphorylation of 2N4R by GSK-3β in vitro (191, 193), we believe this site could be 





phosphorylation sites for each isoform.  Based upon these same previous papers 
showing multiple sites phosphorylated over an entire monomer population, despite 
only having 2 moles of phosphate per mole of tau (191, 193), we believe 
phosphorylation occurs on the tau isoforms at multiple sites as well.  Based on these 
data, it would be difficult to conclude that GSK-3β preferentially phosphorylates any 
particular isoform in vitro.  More discussion on GSK-3β phosphorylation of the tau 
isoforms can be found in Chapter 5. 
 
Although the level of GSK-3β phosphorylation was approximately equal, there were 
differences in the effects on isoform functions.  As expected, four repeat tau isoforms 
bound more tightly to microtubules than did three repeat isoforms.  Phosphorylation 
by GSK-3β decreased the average Kd of 0N3R, 0N4R and 2N4R, but not at 
statistically significant levels due to the variability in the data.  The 2N3R isoform 
bound more tightly to microtubules upon phosphorylation, which is not 
unprecedented for the effects of phosphorylation on tau-microtubule interactions 
(153). The largest differences were observed for the 1N isoforms. Both 1N3R and 
1N4R had approximately 3- fold reductions in microtubule binding following GSK-
3β phosphorylation. While phosphorylation with GSK-3β affects microtubule binding 
differently for each isoform, these effects are small as compared to kinases (such as 
p110MARK at S262) which cause a complete loss in microtubule binding of tau (218).  
Loss of microtubule binding by increased phosphorylation is thought to play a role in 





The effect of GSK-3β phosphorylation on the ARA induction of tau polymerization 
also differed between isoforms. In general, phosphorylation decreased the amount of 
detectable polymerization by ThS fluorescence for the 4R isoforms and had little 
effect on the polymerization of 3R isoforms. It is difficult to assess the amount of 
polymerization detected by LLS since the phosphorylation process seemed to increase 
the tendency of several isoforms to cluster into larger structures. These larger 
structures can potentially result in aberrant scattering (120, 194, 219, 220). The 
largest changes observed due to phosphorylation occurred with filament morphology 
as viewed by TEM. When compared to the unphosphorylated state, each isoform 
tended to increase in length and some showed increased affinities between polymers. 
However, the physiological relevance of such changes in morphology is unknown. 
GSK-3β phosphorylation influences each of the tau isoforms differently, although 
these changes appear to be small in comparison to the inherent differences in the non-
phosphorylated proteins. For example, GSK-3β phosphorylation reduces the ARA 
induced polymerization of the 4R isoforms, but the phosphorylated versions still 
polymerize to a greater degree than the non-phosphorylated 3R isoforms. GSK-3β 
phosphorylation of tau isoforms does alter their microtubule binding in a variable 
manner, but these changes are small, with the greatest effect on binding being an 
approximate 3-fold reduction in binding. 
 
In conclusion, GSK-3β phosphorylation has different impacts on the functions of the 





appears to be less significant than the pre-existing differences in isoform function 
based on their primary structure.  These inherent differences in the isoforms seem to 
react differently to the local environment that appears to be the major determinant of 
the amount of polymerization. Increasing a localized concentration of 
hyperphosphorylated tau along the axon could drive aggregation, as shown previously, 
where increased concentrations of proteins that form amyloid show increased 
filament formation in vivo (226-228).  It is unlikely however, that GSK-3β is the only 
kinase involved in this process as we only saw mild effects on microtubule binding.  
This work is therefore a vital first step in understanding the effects of phosphorylation 






Chapter 4- Hsp70 Differentially Affects Tau Isoforms 
 
4.1 Introduction 
The microtubule associated protein tau exists as six alternatively spliced isoforms (5).  
Alzheimer’s disease (AD) is the most prevalent tauopathy.  However, AD is unique in 
that tau is neither mutated nor is there any change in the relative levels of tau isoform 
expression as compared to aged matched controls (11).  This indicates post-
translational modifications and interactions with other cellular proteins could play a 
major role in AD pathogenesis.  We have shown previously that tau isoform 
polymerization is affected by the buffer conditions, the type of inducer for 
polymerization used and post-translational modifications (150).  The polymerization 
differences caused by changes in the local environment indicate each may have a 
distinct role in the progression of neurodegeneration.   
 
Molecular chaperones have multiple roles which include: preventing inappropriate 
aggregation of hydrophobic regions of misfolded proteins, targeting proteins to 
subcellular compartments, and assisting in degradation of proteins (reviewed in 
(160)).  Heat shock protein 70 kDa (Hsp70) is the 70 kDa inducible form of a class of 
proteins that are upregulated in response to stress, termed heat shock proteins 
(reviewed in (171)).  Hsp70 levels are normally low in central nervous system 
neurons, but can be increased in response to stress (reviewed in (229)).  Hsp70 acts 
by binding hydrophobic regions of a substrate protein in its substrate binding domain 





interaction with the substrate (reviewed in (230)).  Hsp70 then can independently 
assist in refolding, transfer the protein to the Hsp90 system, or transfer the protein the 
chaperonin system for refolding (reviewed in (230)).  Chaperonins are larger 
complexes that provide an isolated environment where the misfolded protein can 
refold in the absence of other misfolded proteins.  Therefore, Hsp70 reduces protein 
misfolding and aggregation under conditions that would favor protein misfolding. 
 
AD patients show an elevated level of stress response proteins.  Therefore, recent 
work has focused on elucidating the role of chaperones in AD. AD hippocampal 
sections show elevated expression of Hsp70/90, as compared to aged matched 
controls (183, 187).  In specific hippocampal neurons there is an inverse relationship 
of tau aggregation and Hsp70/90 levels (183).  Hsp70 has been shown to reduce 
abnormal tau by increasing its degradation and dephosphorylation (183, 185).  Also, 
increased levels of Hsp70/90 promote tau solubility and microtubule binding in 
cellular models  (183).  Both the constitutively active (Hsc70) and inducible (Hsp70) 
forms of Hsp70 have been shown to bind tau directly (186).  Inhibition of Hsp70 
ATPase activity has been show to increase proteasomal degradation of tau in cell 
culture (231).  Finally, previous studies have shown that heparin induced 2N4R tau 
polymerization with Hsp70 and Hsp40 is lowered compared to tau only controls (187).   
 
The previous work on Hsp70/tau interactions has shown Hsp70 could be used to 





Hsp70 and tau levels in specific AD hippocampal neurons (187). Also, previous 
results show tau isoforms do not respond similarly to changes in the local 
environment (150).  Finally, tau has been shown to have an increased affinity for 
microtubules in the presence of Hsp70 in COS-1 cells (183).  Therefore, we 
hypothesize that in vitro Hsp70 would differentially affect the polymerization and 
microtubule assembly properties of tau isoforms.  This hypothesis was examined by 
assaying inducer-mediated tau polymerization using arachidonic acid, heparin sulfate, 
and Congo Red, in vitro, using right angle laser light scattering (LLS), thioflavine S 
fluorescence (ThS) and transmission electron microscopy (TEM) for extent and 
morphology of filament formation, as previously described (51, 150, 189, 191-195, 
203).  Microtubule assembly was examined using a commercially available 
fluorescence kit in the presence and absence of Hsp70. We found that Hsp70 inhibits 
inducer mediated tau polymerization in an isoform specific manner, differentially 
affects the rate and total amount of tubulin polymerization and can affect both 
polymerization and microtubule assembly.   
 
4.2 Results 
4.2.1 Hsp70 inhibits ARA induced 2N4R tau polymerization 
Because it has been shown that Hsp70 binds tau and prevents heparin induction of 
polymerization, we sought to determine whether Hsp70 can inhibit ARA induction of 
2N4R tau polymerization.  The reactions were incubated 18 hours and the resulting 






Figure 4.1. Hsp70 inhibition of ARA induced 2N4R tau polymerization. 4 µM 
2N4R tau and 150 µM ARA was incubated in the presence of various amounts of 
Hsp70 (0-2 µM) for 18 hrs at 37 oC.  Polymerization was measured by (A) LLS and 
(B) ThS fluorescence.  Data is in arbitrary units and represents the average of 3 trials 
± SEM.  After 18 hrs, polymerization reactions for (C) 0 µM, (D) 0.5 µM, and (E) 1 
µM Hsp70 were visualized by TEM at 3600x magnification, as they correspond to 
approximately 0, 50, and 100% inhibition.  Representative images are shown, scale 





low concentrations of Hsp70 there was little observable effect.  Increasing 
concentrations of Hsp70 reduced the amount of tau polymerization observed.  At a 
2:1, tau: Hsp70 ratio, polymerization of tau was nearly completely inhibited.  Data 
was normalized as 100% equal to the highest observable value, and 0% as the lowest 
observable value, and the concentration of Hsp70 needed to reduce the y-value to 
50% was estimated by creating the equation of a line between the two points where 
50% would lie and inserting 50 for the y-value.  The concentration of Hsp70 needed 
to reduce ARA induced 4 µM 2N4R tau polymerization to 50% of the highest value 
was approximately 0.60 ± 0.07 µM as measured by ThS fluorescence and 0.64 ± 0.08 
µM as measured by LLS.  To further determine if Hsp70 inhibits tau polymerization, 
samples of the 2N4R reactions were taken and visualized by transmission electron 
microscopy (TEM) (Fig 4.1C-E).  Compared to the control reaction without Hsp70 
(Fig 4.1C), increasing concentrations of Hsp70 showed a noticeable decrease in 
filament lengths longer than 25 nm (Fig 4.1D, E).  While there was also an increase in 
electron dense material shorter than 25 nm with increasing concentrations of Hsp70, a 
similar increase was observed by TEM in the absence of tau (data not shown).  
Density smaller than 25nm were therefore not included in any quantitative analysis of 
TEM data. 
 
4.2.2 Other inducers of tau polymerization 
The ability of Hsp70 to inhibit the polymerization of tau in the presence of other 





induced tau polymerization reactions were analyzed by LLS (Fig 4.2A) and TEM 
(Fig 4.2B-D).  ThS analysis was not performed because CR obscures ThS 
fluorescence.  The concentration of Hsp70 required to reduce tau polymerization by 
50% was approximately 0.25 ± 0.01 µM.  Samples of reactions were visualized by 
TEM (Fig 4.2B-D).  Upon addition of Hsp70, a decrease in filament lengths and an 
increase in the number of filaments were observed (Fig 4.2C, D) as compared to 
reactions without Hsp70 (Fig 4.2B).  The ability of Hsp70 to suppress heparin sulfate 
induction of tau polymerization was examined by incubating 2N4R tau with varying 
concentrations of Hsp70 in the presence of heparin.  Reactions were analyzed by ThS 
(Fig 4.3A) and TEM (Fig 4.3B-D).  Reactions were not analyzed by LLS because 
LLS of reactions in the absence of tau, but the presence of Hsp70, had similar 
scattering as those reactions in the absence of Hsp70.  The concentration of Hsp70 
required to reduce tau polymerization by 50% was approximately 0.76 ± 0.04 µM.  
Visualization of samples by TEM without Hsp70, revealed only very long filaments 
(Fig 4.3B).  These filaments were so long that the ends did not fit into a 6 µm by 6 
µm field of view.  Upon addition of Hsp70, filament lengths decreased and the 
number of filaments increased (Fig 4.3C, D).  
 
When comparing inhibition curves, 50% inhibition values and TEM images of 
polymerization reactions, it is evident that Hsp70 has similar effects on blocking tau 
polymerization induced by ARA, CR and heparin.  These three compounds are 






Figure 4.2. Hsp70 inhibition of Congo red (CR) induced 2N4R tau 
polymerization. 2 µM 2N4R tau and 10 µM CR was incubated in the presence of 
varying amounts of Hsp70 (0-2 µM) for 18 hrs at 37 oC.  Polymerization was 
measured by (A) LLS only because Congo red interferes with ThS fluorescence.  
Data is in arbitrary units and represents the average of 3 trials ± SEM.  After 18 hrs, 
polymerization reactions for (B) 0 µM, (C) 0.5 µM, and (D) 1 µM Hsp70 were 
visualized by TEM at 3600x magnification as they correspond to approximately 0, 50, 






Figure 4.3. Hsp70 inhibition of heparin induced 2N4R tau polymerization. 2 µM 
2N4R tau and 6 µg/ml heparin was incubated in the presence of varying amounts of 
Hsp70 (0-2 µM) for 18 hrs at 37 oC.  Polymerization was measured by (A) ThS 
fluorescence.  Data is in arbitrary units and represents the average of 3 trials ± SEM.  
After 18 hrs, polymerization reactions for (B) 0 µM, (C) 0.5 µM, and (D) 1 µM 
Hsp70 were visualized by TEM at 3600x magnification as they correspond to 
approximately 0, 50, and 100% inhibition.  Representative images are shown, scale 








a proteoglycan.  Therefore, the ability of Hsp70 to suppress the induction by all three 
inducers suggests that the observed inhibition is not inducer specific, but rather 
specific to tau. 
 
4.2.3 Hsp70 acts by slowing the elongation of 2N4R tau 
To determine how Hsp70 is affecting tau polymerization, ARA induced 
polymerization reactions of 2N4R tau and Hsp70 at various concentrations were 
examined over 6 hours using LLS (Fig 4.4).  ThS kinetics were not used as ThS binds 
Hsp70 weakly and also enhances tau polymerization.  When the data were fit to an 
improved model for tau polymerization, we found that the initial nucleation rate did 
not change, but rather the rate of elongation was slowed, as indicated by a less steep 
slope, so that overall the total amount of tau polymerization was lowered with 
increasing Hsp70 concentrations (Table 4.1).   This suggests that Hsp70 would bind 
tau and remain in close association with tau to prevent monomer from adding onto 
filaments. 
 
4.2.4 ATP does not affect Hsp70 inhibition of 2N4R tau polymerization 
Experiments were carried out to determine the role of ATP in the Hsp70 mediated 
inhibition of ARA induced tau polymerization (Figure 4.5).  The concentration of 
Hsp70 was varied in the reactions, at a constant amount of ATP.  4 μM 2N4R tau and 
150 μM ARA was incubated with 0, 1, 2, or 4 μM Hsp70 in the presence (0.5 mM) or 






Figure 4.4 Hsp70 inhibits ARA induced tau polymerization by slowing the 
elongation rate.  4 μM 2N4R was incubated in the presence of 150 µM ARA and 
varying concentrations of Hsp70 (0-0.5 μM) at 37 oC.  LLS readings of each reaction 
were taken at various time points over 6 hours.  Data was fit to the F-W equation 





[Hsp70] (μM) Lag Time (min -1) Rate of Assembly (AU -1 min -1) Extent of Assembly (AU)
0 0.027 ± 0.012 1.002E-3 ± 4.376E-5 167.800 ± 5.083       
0.125 0.030 ± 0.011 1.773E-4 ± 1.008E-4 186.000 ± 12.430 ** 
0.25 0.019 ± 0.005 7.117E-16 ± 5.792E-16 ** 125.400 ± 6.281 ***  
0.375 0.014 ± 0.004 1.903E-16 ± 1.466E-17 ** 86.270 ± 8.204 ***
0.5 0.023 1.710E-15 ** 16.900***  
Table 4.1 LLS kinetics of ARA induced 2N4R polymerization with varying 
Hsp70 concentrations.  Data from fitting Figure 4.4 to F-W equation.  Data is shown 
as the average of 3 trials ± SEM, and asterisks denote significant differences (* = 
p<0.05, ** = p<0.01, *** = p<0.001) from the 0 µM Hsp70 control as determined by 





decreased with increasing concentrations of Hsp70 and that the addition of ATP did 
not influence Hsp70 inhibition of tau polymerization.  A possible explanation of the 
data could be that 4 μM Hsp70 exhaust the ATP pool quicker than the 1 μM Hsp70.  
To examine this possibility we kept the ratio of ATP to Hsp70 constant.  4 μM 2N4R 
tau was incubated in the presence of either no ATP/Hsp70, 0.5 mM/1 μM ATP/Hsp70, 
1 mM/2 μM ATP/Hsp70, or 2 mM/4 μM ATP/Hsp70.  We found that with increasing 
concentrations of Hsp70 there was no difference between the 500:1 ATP/Hsp70 ratio 
and just adding 500 mM ATP.  These results indicate the addition of ATP has no 
effect on Hsp70 inhibition of tau polymerization.  
 
4.2.5 Addition of Hsp70 after filament formation slightly decreases 
filament lengths 
We have shown that Hsp70 can inhibit inducer mediated tau polymerization when 
added to the reaction at the beginning; however, Hsp70 and other chaperones also 
have an ability to disassemble aggregates.  Hsp70 is not known to disassemble large 
aggregates. Hsp104 forms a hexamer that accomplishes this. However, Hsp70 could 
aid in the process.  2N4R tau was polymerized in the presence of ARA and in the 
absence of Hsp70 overnight at 37 oC (Fig 4.6A). Hsp70 at 1 μM was then added for 
18 hours (Fig 4.6B), visualized by TEM and filament lengths were analyzed by Image 
Pro Plus (Fig 4.6C, D).  The number and mass of small filaments increased in the 
presence of Hsp70, while the number and mass of medium length filaments decreased 






Figure 4.5 The contribution of ATP to Hsp70 inhibition of tau polymerization. 
ATP at various concentrations was added to Hsp70 at varying concentrations and 150 
µM ARA induced 4 µM 2N4R tau reactions.  Reactions without ATP (black), with 
500 mM ATP, or keeping the ATP/Hsp70 ratio at 500:1 were examined by LLS (left) 







Figure 4.6 Hsp70 partially disassembles ARA induced tau filaments in the 
presence of ATP.  Pre-formed ARA (150 µM) induced 2N4R tau (4 µM) filaments 
without Hsp70 (A) and with 1 μM Hsp70 (B), in the presence of 2 mM ATP, were 
incubated 18 hours.  Images were analyzed using Image Pro Plus to determine 
filament lengths with a minimum size of 25 nm.  Data for each image was then 
counted for inclusion in one of the following ranges: short (between 25 nm and 50 
nm), medium (between 50 nm and 100 nm), or long (greater than 100 nm).  The mean 
± SEM of 5 fields is displayed for each range for length (C) and total filament mass 
of that range (D).  TEM images of pre-formed ARA induced 2N4R tau filaments 
without ATP and without Hsp70 (E) or without ATP and with 1 µM Hsp70 (F), 
incubated 18 hours. Asterisks indicate significant differences (p<0.05) between with 





disassembly of filaments, however.  Similar reactions in the absence of ATP were 
performed, however, no difference in filament length was observed.  This indicates 
that Hsp70 can partially disassemble tau filaments, indicating that increasing Hsp70 
levels in a cell that has tau pathology could potentially reverse the effects of 
aggregation.   
 
4.2.6 Hsp70 differentially inhibits other ARA induced tau 
isoform polymerization 
Tau exists as alternatively spliced isoforms that differ greatly in primary sequence, 
with differences from 29 to 89 amino acids as compared to full length 2N4R.  While 
89 amino acids are only 20% differences, this includes the removal of a known 
functional unit, microtubule binding repeat 2.  The absence of repeat 2 (3R isoforms) 
has been shown to have a marked decrease in microtubule binding ability and overall 
polymerization potential as compared to the presence of the repeat (4R isoforms) 
(150).  Therefore, it is possible that Hsp70 will affect tau isoforms polymerization 
differently.  To test this, tau isoforms were incubated with ARA and varying 
concentrations of Hsp70 for 18 hours.  The extent of polymerization was determined 
by LLS (Fig 4.7A) and ThS (Fig 4.7B).  Hsp70 inhibited ARA induced 







Figure 4.7. Hsp70 inhibition of ARA induced tau isoform tau polymerization. 4 
µM tau isoforms and 150 µM ARA were incubated in the presence of varying 
amounts of Hsp70 (0-2 µM) for 18 hrs at 37 oC.  Polymerization was measured by (A) 
LLS and (B) ThS fluorescence.  Data is in arbitrary units and represents the average 







0N3R 0.19 ± 0.03 0.16 ± 0.03
1N3R 0.13 ± 0.01 0.12 ± 0.01
2N3R 0.10 ± 0.01 0.09 ± 0.01
0N4R 0.71 ± 0.08 0.31 ± 0.03
1N4R 0.61 ± 0.05 0.66 ± 0.06
2N4R 0.60 ± 0.07 0.64 ± 0.08
[Hsp70] (µM)  for 50% tau polymerization
 
ThS 50% values LLS 50% values
Newman-Keuls Multiple Comparison Test Newman-Keuls Multiple Comparison Test
Mean Diff. q Significant? P < 0.05? Mean Diff. q Significant? P < 0.05?
2N3R vs 0N4R -0.61 12.24 Yes 2N3R vs 1N4R -0.57 12.75 Yes
2N3R vs 1N4R -0.51 10.23 Yes 2N3R vs 2N4R -0.55 12.3 Yes
2N3R vs 2N4R -0.5 10.03 Yes 2N3R vs 0N4R -0.22 4.919 Yes
2N3R vs 0N3R -0.09 1.806 No 2N3R vs 0N3R -0.07 1.565 No
2N3R vs 1N3R -0.03 --- No 2N3R vs 1N3R -0.03 --- No
1N3R vs 0N4R -0.58 11.64 Yes 1N3R vs 1N4R -0.54 12.07 Yes
1N3R vs 1N4R -0.48 9.632 Yes 1N3R vs 2N4R -0.52 11.63 Yes
1N3R vs 2N4R -0.47 9.431 Yes 1N3R vs 0N4R -0.19 4.249 Yes
1N3R vs 0N3R -0.06 --- No 1N3R vs 0N3R -0.04 --- No
0N3R vs 0N4R -0.52 10.43 Yes 0N3R vs 1N4R -0.5 11.18 Yes
0N3R vs 1N4R -0.42 8.428 Yes 0N3R vs 2N4R -0.48 10.73 Yes
0N3R vs 2N4R -0.41 8.227 Yes 0N3R vs 0N4R -0.15 3.354 Yes
2N4R vs 0N4R -0.11 2.207 No 0N4R vs 1N4R -0.35 7.826 Yes
2N4R vs 1N4R -0.01 --- No 0N4R vs 2N4R -0.33 7.379 Yes
1N4R vs 0N4R -0.1 --- No 2N4R vs 1N4R -0.02 0.4472 No  
Table 4.2. Concentration of Hsp70 (in µM) required to inhibit the maximum 
ARA induced tau isoform polymerization by 50% and p-values comparing each 
data set. Data given in the top part is the mean ± SEM of 3 trials.  Comparisons were 





While all tau isoform polymerization was inhibited with increased Hsp70 
concentrations, differences between isoforms were observed.  In the absence of 
Hsp70, 3R and 4R, isoforms have approximately the same ThS values (Fig 4.7B), 
while LLS values of reactions without Hsp70 are more varied (Fig 4.7A).  At low 
Hsp70 concentrations (less than 0.25 µM), there was a dramatic decrease in 
polymerization for 3R isoforms, while 4R isoforms had no change.  At 0.5 µM Hsp70, 
polymerization reactions containing 4R isoforms began to decrease while reactions 
containing 3R isoforms were completely inhibited.  2N3R was inhibited at lower 
concentrations of Hsp70 as compared to 0N3R and 1N3R.  There were no discernable 
differences between the numbers of N-terminal exons in the 4R isoforms.  The 
concentration of Hsp70 required to inhibit tau polymerization 50% from the 
maximum LLS or ThS value for each tau isoform and the results of a one-way 
analysis of variance (ANOVA) to determine if the means of the isoforms are 
significantly different is reported in Table 4.2.  The only significant difference for 
ThS values when comparing the concentration of Hsp70 required for 50% inhibition 
of tau polymerization is that the 3R isoforms are inhibited at a lower concentration 
than 4R isoforms.  For LLS, the 3R isoforms are significantly different from the 4R 
isoforms, and 0N4R is significantly different from the other 4R isoforms.  TEM 








4.2.7 TEM analysis of tau isoform inhibition 
Reactions of ARA induced tau isoform polymerization with Hsp70 were visualized 
by TEM (Fig 4.8).  TEM revealed a shortening of filaments indicating the decrease in 
LLS and ThS values correspond to a decrease in filament lengths.  TEM images of 
polymerization reactions were quantitated using a 25 nm cutoff filter to account for 
Hsp70 background (Fig 4.9).  Hsp70 reduced the overall number and length of all of 
the tau isoform filaments, but the patterns of inhibition were not the same.  For 
example, upon addition of Hsp70 to 0N3R and 0N4R there is a decrease in the 
number of short and medium length filaments while the number of long filaments 
stay about the same.  
 
The data for 0N4R fits this model if 0.5 µM is used as the start point instead of 0 µM 
because large aggregates described previously (150) seen in the absence of Hsp70, 
and are difficult to quantitate because we can not determine filament ends, form less 
well in the presence of increasing Hsp70, creating an artificial increase in filament 
number (Fig 4.10).  For 1N3R and 2N3R, the number of short filaments increases, the 
number of medium length filaments stays about the same and the number of long 
filaments decreases.  1N4R and 2N4R, which requires more Hsp70 than their 3R 
counterparts to reach complete inhibition, showed relatively no change in the number 
of short filaments, but a decrease in the number of medium and long filaments.  These 
data indicates that as Hsp70 concentrations are increased, the elongation of tau 







Figure 4.8. Electron micrographs of Hsp70 inhibited tau isoform polymerization 
with ARA.  After 18 hrs, polymerization reactions from Figure 4.7 were visualized 
by TEM at 3600x magnification. Representative images at 3600x magnification of 3R 
isoforms are shown of (left column) 0 µM, and (right column) 0.5 µM Hsp70, and 4R 
isoforms of (left column) 0 µM, and (right column) 1 µM Hsp70.  Scale bars 






Figure 4.9. Electron micrograph filament length distributions of Hsp70 inhibited 
tau isoform polymerization with ARA.  Images of polymerization reaction from 
Figure 4.7 were analyzed using Image Pro Plus to determine filament lengths with a 
minimum size of 25 nm.  Data for each image was then counted for inclusion in one 
of the following ranges: short (between 25 nm and 50 nm), medium (between 50 nm 
and 100 nm), or long (greater than 100 nm).  The mean ± SEM of 5 fields is displayed 






Figure 4.10. 0N4R aggregates artificially skew quantitation of electron 
microscopy data.  After 18 hrs, polymerization reactions of ARA induced 0N4R tau 
polymerization with varying concentrations of Hsp70 were visualized by TEM at 
3600x magnification.  (A) 0 µM Hsp70 (B) 0.0625 µM Hsp70 (C) 0.125 µM Hsp70 
and (D) 0.5 µM Hsp70.  As the concentration of Hsp70 is increased, the size of 
infrequent large aggregates seems to decrease and filaments seem to become 
distributed more evenly across the grid.  This suggests the data for quantitation of 





4.2.8 Hsp70 affects tau associated microtubule assembly 
Because tau is a microtubule associated protein, and previous work has shown that 
Hsp70 increases tau protein affinity for microtubules in cells (183), the influence of 
Hsp70 on the microtubule assembly rate of the different tau isoforms was examined.  
A commercially available fluorescence based microtubule assembly assay was used 
(Cytoskeleton).  Each tau isoform was incubated with and without Hsp70 (at a 1:1 
ratio) and tubulin.  This ratio of tau to Hsp70 is enough to completely inhibit tau 
polymerization in vitro.  Microtubule assembly reactions were run concurrently with 
taxol, Hsp70 and buffer only controls.  The taxol control was used to normalize data 
sets from different trials (Fig 4.11).  Microtubules assembled in the presence of taxol 
and all tau isoforms.  The addition of Hsp70 or buffer alone to tubulin reactions failed 
to increase tubulin assembly to detectable levels.  In general, tau reactions that lack 
Hsp70 assembled tubulin to a higher steady state, and usually at a faster rate as 
compared to reactions that included tau and Hsp70.  The data was fit to a nonlinear 
Gompertz function to determine lag, apparent rate of polymerization and maximum 
polymerization (192, 197, 219).  0N3R and 1N4R showed significant differences 
(p<0.05) for all three attributes upon addition of Hsp70 (Table 4.3).  Hsp70 shortened 
the lag time, slowed the rate of microtubule assembly, and reduced the total extent of 
microtubule assembly in the presence of 0N3R.  Hsp70 shortened the lag time, and 
reduced the total extent of assembly, but increased the rate of microtubule assembly 
for 1N4R.  Hsp70 significantly affected the overall extent of microtubule assembly 






Figure 4.11. Microtubule assembly with tau isoforms and Hsp70. 1 µM tau 
isoforms were incubated with tubulin in the presence or absence of 1 µM Hsp70 at 37 
oC for 1 hr.  Fluorescent readings at 355 nm excitation and 460 nm emission were 
taken every minute.  A taxol only control was used to normalize data from different 
runs, but the tau isoform and its corresponding tau +Hsp70 was always in the same 






Hsp70 Ymax (RFU) kapp (min
-1) lag (min)
- 0.88 ± 0.01 0.24 ± 0.01 3.72 ± 0.03
+ 0.72 ± 0.01 0.19 ± 0.00 3.27 ± 0.05
- 0.82 ± 0.01 0.20 ± 0.00 6.18 ± 0.42
+ 0.79 ± 0.00 0.19 ± 0.00 6.76 ± 0.06
- 0.83 ± 0.01 0.15 ± 0.01 4.25 ± 0.41
+ 0.72 ± 0.02 0.14 ± 0.01 4.66 ± 0.37
- 0.82 ± 0.02 0.19 ± 0.01 3.58 ± 0.22
+ 0.72 ± 0.01 0.19 ± 0.01 3.19 ± 0.13
- 0.82 ± 0.01 0.14 ± 0.00 6.05 ± 0.13
+ 0.77 ± 0.01 0.18 ± 0.01 4.21 ± 0.30
- 0.79 ± 0.10 0.13 ± 0.01 6.19 ± 0.34
















Table 4.3. Statistics of microtubule assembly with tau isoforms and Hsp70. 
Microtubule polymerization data were fit to the Gompertz growth curve to analyze 
the lag time, kapp (proportional to rate), and maximum polymerization. Statistical 
significance (* = p<0.05, ** = p<0.01, *** = p<0.001) as determined by an unpaired 
t-test is denoted by an asterisk for differences between with and without Hsp70 for 






 Hsp70 levels are increased in AD brains, most likely in response to oxidation 
and inflammation, known to be associated with AD (232-236).  The inverse 
relationship of Hsp70 levels and tau pathology in specific hippocampal neurons 
indicates the cell could respond to a specific signal to upregulate Hsp70 to increase its 
ability to respond to the presence of abnormal tau and prevent aggregation.  
Previously published cell culture results showed an interaction between Hsp70 and 
0N3R or 2N4R tau, resulting in decreased insoluble tau and an increase in tau 
association with microtubules (183).  Due to the Hsp70 and tau interactions 
previously reported, we hypothesized that Hsp70 would affect tau protein dysfunction 
by inhibition of inducer mediated tau polymerization in vitro.  2N4R tau 
polymerization with various inducers of polymerization, arachidonic acid, Congo red 
and heparin was inhibited upon addition of Hsp70.  This indicates that Hsp70 is a 
general inhibitor of tau polymerization and not dependent upon the inducer used.  
This is significant since the physiological inducer of tau polymerization is unknown.  
However, our data suggests that Hsp70 will inhibit any inducer because inhibition is 
likely protein specific and not inducer specific.  We also determined that Hsp70 
inhibits tau elongation, not nucleation. 
 
We found that Hsp70 can act independently of ATP binding, which has been 
previously described (237).  This ATP independent binding of Hsp70 is interesting as 





Hsp70 and tau and not a refolding mechanism.  In the ADP bound state, Hsp70 has a 
higher affinity for its substrate and a slower exchange rate.  Therefore, in our in vitro 
system we conclude Hsp70 interacts with tau in a high affinity state in the absence of 
ATP.  With the addition of ATP to the reactions, Hsp70 will hydrolyze ATP, but 
remain bound to tau similar to a reaction without ATP.  In a neuron, there would be 
other factors such as co-chaperones and continuous cycling of ATP and ADP states.  
While we are not replicating what is most likely happening in a neuron, we show 
Hsp70 can bind tau in the absence of ATP and prevent aggregation.   
 
Finally, we found tau filaments can be partially disassembled by Hsp70 in the 
presence of ATP although complete disassembly was not observed.  Similarly, ATP is 
most likely required for partial disassembly as reactions without ATP had little 
observable effect.  These data suggest increasing Hsp70 levels in a neuron before 
2N4R tau polymerization takes place could increase the amount of inhibition of tau 
polymerization, and there is a potential to reverse the effects of tau polymerization by 
increasing the levels of heat shock proteins. 
  
The alternative splicing of tau isoforms could influence the global hairpin structure 
commonly believed to be adopted by tau in solution (Fig 4.12) (238).  These 
differences in structure could allow Hsp70 to interact with different residues of 
different tau isoforms (see Fig 5.1 for predicted Hsp70 binding sites). Therefore, we 






Figure 4.12 The global hairpin configuration of tau.  Tau is thought to adopt a 
global hairpin conformation in solution.  When the C-terminus is in close contact with 
microtubule binding repeat 3, tau is thought to be in its soluble form.  When the N-
terminus is in close contact with microtubule binding repeat 3, tau can form filaments.  
This later specific conformation is confirmed by the Alz50 and MC1 antibodies that 
bind to amino acids in both the N-terminus and amino acids in repeat 3, and only bind 





tau isoforms.  3R isoforms were found to be inhibited at lower concentrations of 
Hsp70 than 4R isoforms.  Previous results have shown that a constitutively active 
heat shock protein, Hsc70, which shares a 86% sequence identity with Hsp70, can 
bind to tau isoforms (186).  Hsc70 bound to 3R isoforms with a lower KD than 4R 
isoforms.  This difference in binding is thought to be due to the site of binding of 
Hsc70 to tau. 275VQIINK280 and 306VQIVYK311 are regions flanking microtubule 
binding repeat 2, which is alternatively spliced as exon 10 in 3R isoforms, and are 
thought to play a role in tau polymerization.  Hsp70 therefore, could bind to the one 
available site on 3R isoforms, while it has two options on 4R isoforms. Thus, at low 
concentrations of Hsp70, 3R isoforms are inhibited perhaps because more tau protein 
has Hsp70 bound than 4R isoforms that may have a polymerization site still available.  
We also observed that 2N3R tau were inhibited 50% of maximum polymerization at a 
lower Hsp70 concentrations as compared to 0N3R and 1N3R, indicating that perhaps 
exon 3 is also involved in Hsp70 inhibition of tau polymerization.  This could be due 
to the longer N-terminus affecting the global hairpin conformation and perhaps 
allows the 306VQIVYK311 site to be more accessible.  We did not observe a dramatic 
difference between the 4R isoforms that supports the idea that having two 
polymerization sites allows tau to polymerize in the presence of Hsp70 bound at one 
site. 
  
Since the predicted site of Hsp70 binding is near the microtubule binding repeat 





Previous results show increased Hsp70 levels in cell culture result in increased tau 
associated with microtubules.  This indicates Hsp70 is not interfering with the 
microtubule binding function; however, Hsp70 could affect the microtubule assembly 
function of tau by removing the ability of one or more microtubule binding repeats to 
bind to assembling microtubules.  This phenomenon has been described previously 
for tau where phosphorylation at certain sites changes the assembly properties, but 
not the microtubule binding properties of tau (156).  We hypothesized that Hsp70 
would differentially affect the tau isoforms ability to assemble microtubules in vitro, 
due to differences in primary sequence between isoforms.  Even in the presence of 
equimolar concentrations of Hsp70, tau isoforms robustly assembled microtubules.  
However, Hsp70 significantly affected all three assembly properties (lag, kapp, and 
max) of 0N3R and 1N4R, but to various degrees.  0N4R and 2N3R were also affected 
significantly in terms of maximum assembly.  This indicates that Hsp70 acts 
specifically on certain isoforms to change their ability to assemble microtubules, 
however assembly can still occur. Because 0N3R is the fetal form, increases in Hsp70 
levels could play a role in microtubule formation in developing neurons. 
  
We have shown that increased Hsp70 concentrations inhibit tau isoform 
polymerization. This inhibition is independent of polymerization inducer used, and 
independent of ATP.  However, ATP could be useful in disassembling preformed tau 
filaments as reactions without ATP had little observable effect.  Hsp70 also was 





isoforms ability to assemble microtubules slightly.  These data, and previous results, 
indicate that increasing Hsp70 levels can inhibit the dysfunction of tau 
(polymerization) while allowing the normal microtubule assembly and binding 
function to remain intact.  However, alterations in post-translational modifications, 
such as phosphorylation, could play a role in how Hsp70 interacts with tau isoforms.  
Changes in the post-translational modification of tau isoforms can alter the global 
hairpin conformation and potentially increase or decrease Hsp70 binding.  These data 
could also explain the inverse relationship of molecular chaperones to tau pathology 
in AD affect hippocampal neurons, and could in part explain differences seen 






Chapter 5-Conclusions and future directions 
Alzheimer’s disease was first described in 1907.  Tau protein, which forms 
neurofibrillary tangles, a pathological hallmark of AD, was not discovered until 1975.  
Even then, tau was not implicated to play a role in neurodegeneration until the 1980s.  
Given this, the tau field is relatively new at about two decades.  Further, research of 
tau is hampered by the lack of structural data to determine how tau undergoes the 
transition from natively unfolded to an amyloid form.  Techniques that have been 
employed as ways to investigate tau folding include using small fragments of tau, or 
looking at lower resolution such as FRET studies that examine if two regions of the 
protein come in close contact with each other upon folding.  An even more basic 
question exists as prior to this dissertation work, little was known about how 
alterations to tau affected filament formation.  For instance, the physiological 
inducers for tau polymerization in neurons remain unknown, if there are any.  Also, 
prior to this work, differences between tau isoforms were rarely compared.  Most 
research is performed on 2N4R tau, as it includes all the exons missing from other tau 
isoforms.  This makes comparison of the results between isoforms easier as 
differences between an isoform and 2N4R tau could be attributed to the missing 
exons.  2N4R also produces robust filaments upon polymerization with inducer 
molecules, and binds well to microtubules, making it an attractive isoform to work 
with.  This work was endeavored upon to support a concept that tau research should 






Because the six tau isoforms differ largely in their primary sequence, it follows that 
there should be differences in both how they function normally by binding to tubulin, 
and how they polymerize and cause disease.  The results presented in Chapter 3 show 
that 3R isoforms are not able to polymerize to the same extent as 4R isoforms. This is 
thought to be due to the absence of 275VQIINK280 that is present in exon 10.  This 
sequence has been shown to be important in tau polymerization as it is a minimal 
component of amyloid fiber formation (121, 239, 240).  Also in Chapter 3, we show 
that the optimal ratio of inducer to tau isoform differs between isoforms and in fact, 
under certain conditions, heparin fails to induce polymerization of 3R isoforms. This 
suggests that in a cell, at a given inducer concentration, certain tau isoforms can 
polymerize at different rates than others.  This also indicates that the local cellular 
environment plays a large role in tau dysfunction.  The environment refers to the local 
concentration of an inducer between neurons.  While we do not know what the 
physiological inducer is, it is difficult to assess how the relative levels change over 
time.  Also, the environment refers to the local concentration of tau, which can vary 
from the cell body to the end of the axon, and if hyperphosphorylated could lead to 
changes in distribution along the axon (see section 1.5).  Chapter 3 also demonstrated 
that even though all six isoforms can be phosphorylated by GSK-3β, they do not alter 
their filament morphologies, or even polymerization to the same degree.  What we 
determined as the more important factor in regulating tau polymerization was the 
primary sequence, rather than GSK-3β phosphorylation.  Finally, GSK-3β had 





microtubule binding of tau isoforms, however in the case of 1N4R, microtubule 
affinity was increased. What this chapter indicates overall is that the six tau isoforms 
are not equal, and in order to model how tau dysfunction causes neurodegeneration, 
investigating specific effects of all six isoforms is required.  It will not be sufficient to 
investigate just one isoform and apply that model to the others.  GSK-3β has been 
shown to accumulate near NFTs in the cell body in transgenic mice models, but not in 
aged matched controls, indicating the localization of GSK-3β adds to the 
environmental complexity of tau aggregation (241).   Our results indicate that GSK-
3β, the kinase widely believed to play the major role in hyperphosphorylation of tau, 
cannot most likely act alone.  We believe this is because GSK-3β failed to induce 
major changes in microtubule binding or tau aggregation into NFTs.  It is possible 
that upon phosphorylation with multiple kinases, larger changes may occur. 
 
The original rationale for performing the experiments in Chapter 3 Part 2 was to 
extend previous work performed in our lab on GSK-3β phosphorylation and 
pseudophosphorylation of 2N4R to the other tau isoforms (191-193).  While we 
cannot directly compare all the tau isoform results to this work, we can compare our 
2N4R results, and if similar to the previous results, make the assumption that the 
isoform results we observe are significant.  The results of GSK-3β phosphorylation 
with 2N4R prior to and after polymerization showed that 2N4R was able to form 
what are termed “tangle-like” aggregates (191, 193). We see similar structures upon 





into clusters, indicating phosphorylation of tau plays a role in the aggregation of 
filaments into larger structures such as NFTs.  However, we note that not all tau 
isoforms were found to aggregate into these clusters, indicating that perhaps if 
phosphorylation by GSK-3β can accomplish this for some, there are perhaps other 
kinases that can accomplish clustering for the other tau isoforms.  This clustering is 
despite slightly lower levels of phosphorylation in our results (~1 mole of phosphate 
per mole of tau) as compared to the previous results which saw ~3 moles of 
phosphate per mole of tau (191).  We also saw a similar shift in the 2N4R band by 
SDS-PAGE upon phosphorylation, despite the lower phosphate incorporation.  This 
most likely indicates a less efficient phosphate incorporation rate, but at similar sites 
as to induce a conformational change.  We did not investigate the site specificity of 
the tau isoforms, however with similar levels of phosphate incorporation and a 
corresponding band shift upon phosphorylation between isoforms, we speculate that 
phosphorylation is occurring at similar sites on the various tau isoforms. We can 
attempt to correlate our GSK-3β phosphorylation data to the pseudophosphorylation 
data by examining which mutants are similar in properties to the 2N4R 
phosphorylation form.  Based upon the pseudophosphorylation data examining which 
forms created an SDS-resistant mobility shift, our data is similar to the S396/404E 
and the 6- (199, 202, 205, 231, 396, 404) and 7-phos (199, 202, 205, 231, 235, 396, 
404) mutants, which include the S396/404E mutations (192).  These were the only 
pseudophosphorylation mutants that showed a SDS-resistant mobility shift similar in 





WT 2N4R tau had a similar Kd for both studies and upon phosphorylation with GSK-
3β, 2N4R decreased in affinity to ~0.4 μM where the 6-phos pseudophosphorylation 
mutant decreased the microtubule binding affinity to ~0.4 μM as well.  What is 
interesting is that single and double site mutations of the 6-phos (205, 199+202+205, 
231, 393+404) all had similar Kd values, indicating that GSK-3β may phosphorylate 
any of these sites.  Phosphorylation at any of these sites is possible because we 
believe that in solution, the tau monomer phosphorylated by GSK-3β is a mixture of 
many sites based upon the previous work (191, 193).  Likewise, upon comparison of 
overall polymerization between GSK-3β phosphorylated and pseudophosphorylation 
mutants, in general, most of the pseudophosphorylation mutants had decreased LLS 
values as compared to WT, similar to our observations.  Differences between the two 
studies are observed when examining filament morphologies.  Despite increased 
filament lengths for both studies, the pseudophosphorylation mutants did not show a 
tendency to cluster into tangle-like structures.  This is despite the 6- and 7-phos 
mutant filaments on average being longer than GSK-3β filaments.  However, in a set 
of unpublished data by Qian Sun and T. Chris Gamblin, mixtures of 
pseudophosphorylation mutants did lead to clustering, indicating the various 
phosphorylation states of tau monomers is important for clustering.  Based upon our 
data for GSK-3β phosphorylation of 2N4R tau, we can conclude that we recapitulated 
previous results and that the observations of the other tau isoforms are representative 
of real differences upon phosphorylation with GSK-3β.  Further studies investigating 





of phosphorylation changes affecting functional and dysfunctional properties of tau 
protein.   
 
Over 30 kinases are known to be able to phosphorylate tau under normal and 
physiological conditions.  We have examined GSK-3β phosphorylation of the tau 
isoforms in Chapter 3.  GSK-3β, however, is known to be a kinase that works more 
effectively at primed sites (242).  Primed sites are phosphorylated residues that are 
recognized by GSK-3β, for instance, to signal phosphorylation at a nearby site.  So 
what we describe as mild effects of GSK-3β on tau isoforms could in fact be 
enhanced if tau undergoes phosphorylation by priming kinases such as CDK 5 and 
ERK 1.  In fact, an entire dissertation could be devoted to examining the effects of 
phosphorylation by priming kinases alone and in conjunction with GSK-3β 
phosphorylation.  Similarly, our lab has shown that by making mutations from serine 
and threonine to glutamic and aspartic acid, we can create pseudophosphorylation 
mutants that behave similarly to phosphorylated tau (192).  By using this method, we 
can investigate residue specific changes to tau isoforms.  Each method has its 
drawbacks though.  If we were to use kinases exclusively, the phosphorylation 
process proceeds rapidly, however, we cannot control which residues the kinases will 
phosphorylate on tau.  To this end, our lab has shown that phosphorylation of 2N4R 
tau with GSK-3β phosphorylates tau at about 1-4 moles of phosphate per mole of tau, 
however, up to 11 sites can be phosphorylated by use of phosphorylation site specific 





the same creating a problem of heterogeneous mixtures.  By using kinases to 
investigate phosphorylation in vitro, determination of which sites are phosphorylated 
will be important to understand the results.  Alternatively, if we were to use the 
pseudophosphorylation mutants, there is a long setup time in making mutations in all 
the isoforms at various combinations and then purifying each construct.  We would 
have a more homogeneous mixture of tau monomer when looking at a specific 
mutation of residues; however, in a cell it is unlikely this exists.  The best way to 
approach the question of how phosphorylation by multiple kinases plays a role in tau 
polymerization and loss of function, may be to employ both techniques where 
pseudophosphorylation mutants of priming sites are created and then phosphorylation 
with GSK-3β in vitro occurs.  By doing this we can make sure we examine each 
priming site individually and in combination and then examine how priming affects 
GSK-3β phosphorylation of tau, using site specific phosphorylation antibodies that 
our lab has procured.  Using this technique, we can more precisely examine the role 
phosphorylation plays in regulating tau function and dysfunction.   
 
Chapter 4 provided a different angle on regulation of tau function and dysfunction.  
Instead of looking at post-translational modifications, we examined the role of a 
molecular chaperone, Hsp70, in the mediation of tau polymerization and microtubule 
assembly.  Hsp70 is upregulated in response to stress, such as heat shock, oxidative 
stress, or inflammation and has been found to correlate inversely to the level of tau 





act directly on tau in vitro and prevent its aggregation.  Our data showed that Hsp70 
acts on tau directly, not by binding the inducer, preventing tau polymerization.  
Similar results of 2N4R tau polymerization inhibition with Hsp70 has been shown to 
occur in vitro, supporting our idea that Hsp70 acts direct on tau (187). 
 
Likewise, Hsp70 can act through an ATP independent mechanism to prevent tau 
aggregation as the addition of ATP to polymerization reactions showed similar 
characteristics as reactions without ATP.  The exact mechanism by which this occurs 
is an interesting topic for future studies examining structural changes of Hsp70 and 
tau upon Hsp70 and tau binding.  Previously, ATP independent binding has been 
described in which the substrate binding domain (SBD) of DnaK, the E. coli 
homologue of Hsp70, was shown to bind a peptide in the presence or absence of ATP 
and/or the presence or absence of the ATPase domain (237).  This indicates the 
substrate binding domain can exist in a high affinity state for substrate.  Whether this 
happens in the cell is unknown as the cellular environment contains large amounts of 
ATP.   
 
We found all tau isoform polymerization was inhibited by Hsp70, to varying degrees.  
Most notably the 3R isoforms were inhibited at a lower concentration of Hsp70 than 
the 4R tau isoforms. The mechanism for how this occurs is speculative at this point, 
but Hsp70 is thought to bind to the two hexapeptide regions (275-280 and 306-311), 





therefore two Hsp70 would need to bind one tau in order for polymerization to be 
inhibited, and if only one Hsp70 was bound, the unbound hexapeptide could still be 
involved in polymerization.  Conversely, 3R tau only has one hexapeptide and if 
Hsp70 binds this, there is not a compensatory hexapeptide to allow polymerization to 
still proceed, and is thus inhibited at a lower concentration of Hsp70.  What was also 
of interest is that 2N3R tau was inhibited at a lower concentration of Hsp70 than the 
other 3R isoforms.  This indicates Hsp70 also has an impact on exon 3 as 0N and 1N 
isoforms lack exon 3.  This also indicates that future uses of Hsp70 as a therapeutic 
may need to involve isoform specific interactions as Hsp70 seems to influence 
isoform polymerization differently.  The exact role Hsp70 plays in 2N3R 
polymerization inhibition is unknown.  Based upon what is known about tau 
polymerization however, we can speculate as to a mechanism.  The N-terminus of tau 
is thought to be involved in promotion of tau polymerization, as a truncation of the N-
terminus decreases the polymerization of tau in vitro (243-245).  Based upon a Kyte-
Doolittle hydropathy plot of tau isoforms (Fig 5.1) the 2N isoforms have a patch of 
hydrophobic residues in exon 3, a potential binding site of Hsp70.  If Hsp70 binds to 
the N-terminus and the 275-280 hexapeptide, which could only occur with 2N 
isoforms, then this would mimic N-terminal truncation and potentially explain why 
2N3R is inhibited at a lower Hsp70 concentration than other 3R isoforms.  We also 
found Hsp70 acts on tau to alter the microtubule assembly properties of tau, although 
there is still a large amount of microtubule assembly.  Only two tau isoforms were 





significantly lowered overall amount of microtubule assembly.  In order to determine 
why there is a difference between the isoforms more information would need to be 
determined about the specific interactions of Hsp70 and the individual tau isoform by 
examination of binding affinities for the various tau isoforms. 
 
The results of Chapter 4 are a good indicator that Hsp70 could be a good therapeutic 
target for control of tau aggregation in neurons.  Hsp70 inhibits tau polymerization, 
while still allowing robust microtubule assembly.  However, more information about 
the Hsp70 and tau interaction needs to be determined, most notably where Hsp70 can 
interact on tau.  This proposed interaction, based upon previous studies examining 
Hsc70 and tau interactions (186), would indicate Hsp70 binds to the two hexapeptides 
flanking MTBR 2.  However, it seems that in the case of 2N3R, Hsp70 could bind to 
a part of exon 3 as well.  Examination of a Kyte-Doolittle hydropathy plot of the tau 
isoforms shows potentially large hydrophobic regions where Hsp70 could bind (Fig 
5.1).  Investigation into Hsp70 binding of 2N4R using a variety of techniques has 
resulted in uninterpretable results (see Appendix).  The reason for these results is 
most likely due to technical difficulties, as both Hsp70 and tau are very “sticky” 
proteins that can bind non-specifically to the materials used.  For example, the first 
experiment to test the binding affinity of Hsp70 and 2N4R tau was to bind 2N4R tau 
and Hsp70 to Protein G beads coupled with anti-tau and Hsp70 antibodies (Fig A.1).  
The protein however, was unable to stay bound to the beads.  The second attempt 





histidine tagged Hsp70 (Fig A.4).  However, Hsp70 was able to bind to the nickel 
agarose beads in the absence of tau, despite the fact that Hsp70 with no histidine tag 
did not react with an anti-histidine antibody via western blot (Fig A.3).  The next 
technique to measure binding was isothermal titration calorimetry; however we were 
never able to consistently produce a normal isotherm (Fig A.5-A.8).  We believe this 
is due to the high protein concentrations required to run the experiment, and possible 
dimerization of Hsp70, which upon dilution would result in dissociation and heat 
changes.  We finally tried using the BIAcore surface plasmon resonance technique 
that uses an immobilized ligand on a chip and flows an analyte over the surface; any 
change in the mass on the surface of the chip is measured as a change in the reflection 
of light.  We tried a variety of immobilization combinations (tau antibody, Hsp70 
antibody, 2N4R tau, and histidine tag antibody) and flowed the corresponding analyte 
over the surface.  While we were able to generate results, our control channel (no 
protein coupled to the chip) showed interactions, with both tau (Fig A.9) and Hsp70 
(data not shown), but not with a peptide that can bind to Hsp70 (Fig A.10).  Despite 
the issues with the control panel, we did find the Hsp70 bound a larger amount of 
2N4R tau than 2N3R tau, or a deletion mutant of residues I277, I278, I308, and V309, 
which are hydrophobic residues in the two hexapeptide regions (Fig A.11-13).  This 
verifies that Hsp70 and tau interact with each other and that the two hexapeptide 
regions are targets of Hsp70.  Despite the technical difficulties with the control 
channel, a future direction for this project would be to make peptides, of roughly 11 





BIAcore experiments), that span the regions determined by the hydropathy plot to be 
potential Hsp70 binding sites (Fig 5.1).  These peptides should have less non-specific 
binding to the control channel as seen with the Hsp70 substrate binding domain 
peptide (Fig A.10). 
 
Despite a lack of understanding of how Hsp70 and tau interact, investigation into how 
modifications to tau affect Hsp70 binding is critical to understanding how to prevent 
tau aggregation in a neuron.  Our lab has the resources to test a wide variety of 
mutations and post-translational modification states of tau isoforms.  Because 
hyperphosphorylated tau is so widely involved in the pathogenesis of AD and other 
tauopathies, and having pseudophosphorylation constructs readily available for all the 
isoforms, we can examine how phosphorylation at various sites changes Hsp70 
polymerization inhibition.  The substitution of glutamic and aspartic acid for serine 
and threonine would make these regions less hydrophobic, especially for regions that 
have multiple serines and threonines like the C-terminus.  We would predict that by 
making these regions more negative and decreasing hydrophobicity, tau would still 
potentially be inhibited in its polymerization.   We would also predict that because of 
the decreased hydrophobicity, inhibition of inducer mediated tau polymerization 
would require a larger concentration of Hsp70, consistent with upregulation of Hsp70 
during stress.  In addition, once the residues of tau that Hsp70 can bind to are 
determined, the next interesting question is to ask how Hsp70 inhibits tau 





prevent interactions with other tau monomers?  Alternatively, does Hsp70 create a 
folding intermediate of tau that is unable to polymerize because the hexapeptides are 
buried?  Hsp70 is a good target for modulation of tau dysfunction as Hsp70 levels are 
increased during stress and most likely increases in Hsp70 levels will have a minimal 
impact on other cellular functions as Hsp70 will only bind abnormally folded proteins.  
However, Hsp70 may not be the best candidate for targeting tau.  It would be 
interesting to determine how much better or worse other chaperones, such as Hsp40 
(the co-chaperone of Hsp70), Hsp90, or Hsp104, might be at regulation of tau 
dysfunction.  In addition, within neurons, multiple heat shock proteins work in 
conjunction to regulate protein misfolding.  Examination of the interplay of these 
chaperones in vitro would provide better insight into how to improve tau aggregation 
inhibition.   
 
This dissertation is the culmination of work performed during my graduate school 
tenure.  It has demonstrated that tau isoforms respond differently to their environment 
(summarized in Table 5.1). It has shown that by focusing on one specific tau isoform 
the whole picture is obfuscated, as the tauopathies involve the aggregation and 
modification of various tau isoforms.  This dissertation has shown that the natural cell 
response to prevent aggregation by increased molecular chaperone involvement 
works, but is somehow evaded in AD.  Perhaps in the other tauopathies the 
misregulation of heat shock proteins can result in the variety of tau isoforms found 





understanding how tau isoforms are differentially regulated and involved in 
tauopathies.  Since Hsp70 is a natural stress responder, this work points toward the 
use of inducible cellular proteins, to treat neurodegenerative diseases as a potential 
future therapeutic.  Such therapies could make use of chemical modifiers of Hsp70, 
such as geldanamycin analogues, that have been shown to upregulate Hsp70 in cells.  
These cells, which the current literature suggests have a defective stress response, 
may need help through the use of the analogues, while normal cells would hopefully 













Region 3 Region 4
0N3R 60-AAGHVTQARMVS-71 185-LQTAPVPMPDLKNV-198
0N4R 60-AAGHVTQARMVS-71 185-LQTAPVPMPDLKNV-198
1N3R   89-AAGHVTQARMVS-100 214-LQTAPVPMPDLKNV-227
1N4R   89-AAGHVTQARMVS-100 214-LQTAPVPMPDLKNV-227
2N3R 118-AAGHVTQARMVS-129 243-LQTAPVPMPDLKNV-256
2N4R 118-AAGHVTQARMVS-129 243-LQTAPVPMPDLKNV-256




















2N4R 407-HLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL-441  
Figure 5.1 Predicted hydrophobic regions of tau isoforms.  Hsp70 binds primarily 
to exposed hydrophobic patches of proteins.  Tau isoforms were analyzed using 
ProtScale on ExPASy (http://expasy.org/cgi-bin/protscale.pl) using the Kyte-Doolittle 
(246) hydrophobicity scale at a window size of 11 amino acids.  Regions of 
hydrophobic patches were aligned for each isoform.  Numbers denote amino acid 
residue for the specific tau isoform.  The three regions that differ are 41-51 for the 0N 
isoforms, 70-85 for the 2N isoforms and Region 5 that contains VQIINK (only 
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Appendix- Hsp70 and tau binding studies to date 
This appendix is a record of Hsp70 and tau binding studies that have failed to produce 
useable data.  We have tried (in order) using Protein G beads with tau (Tau12) or 
Hsp70 (SPA810) antibodies to capture tau and Hsp70, and then bind the 
corresponding protein.  Next, we tried using nickel agarose beads to bind histidine 
tagged tau, and capture non-histidine tagged Hsp70.  Next, we tried using isothermal 
titration calorimetry to measure the heat of binding between tau and Hsp70, but could 
not reproduce good data.  Finally, we tried using surface plasmon resonance to 
measure binding of Hsp70 and tau, but found both Hsp70 and tau bind in the empty 
reference channel.  This means we cannot account for non-specific binding in the test 
channels, and results in unreliable data.  The images shown are in support of why we 
chose to use the next set of techniques.  This is meant to be a record for future 







Figure A.1 Hsp70 and 2N4R tau bound to antibodies do not stay bound to 
Protein G beads.  100 µl of Tau12 (anti-tau) or SPA810 (anti-Hsp70) was incubated 
with 50 µl of magnetic Protein G beads for 10 minutes at room temperature.  Beads 
were attracted to one side of tube by a magnet and washed before addition of 2 µM 
tau and 0.5, 1 or 2 µM Hsp70 that had been preincubated at 37 oC for 10 minutes.  
After incubation of proteins with beads for 10 minutes, beads were again attracted to 
one side of the tube, and the supernatant (labeled step 10 sup above) was collected.  
The beads were washed three times and the remaining protein was eluted (labeled 
elution sup above).  Both supernatants, 1 µg of 2N4R tau, and 0.5 µg Hsp70 with a 
molecular weight marker were run on 10% SDS-polyacrylamide gels, stained with 
Coomassie blue and scanned.  The data shows that tau and Hsp70 bind weakly to both 







Figure A.2 SDS-PAGE of thrombin cleavage of Hsp70 to remove histidine tag 
for use in nickel agarose bead precipitation.  Purified Hsp70 was subjected to 
thrombin cleavage to remove the N-terminal histidine tag and run over a Nickel 
column.  Hsp70 without the histidine tag did not bind to the column as indicated by 






Figure A.3 Western blot for the anti-histidine tag of thrombin cleaved Hsp70 to 
remove histidine tag for use in nickel agarose bead precipitation. The fractions 
from Fig A.2 were run again on a 10% SDS-polyacrylamide gel and transferred to a 
PVDF membrane.  Anti-histidine antibody was used to detect the presence of His-
tagged Hsp70.  As seen, no immunoreactivity was present in A1-B12, but was present 
in a sample of uncleaved Hsp70.  This indicates thrombin cleavage of Hsp70 worked 






Figure A.4 Tau and non-his-tagged Hsp70 immunoprecipitation with magnetic 
nickel agarose beads.  0 µg and 5 µg of 2N4R tau and 5 or 10 µg of Hsp70 was 
incubated at 25 oC or 37 oC for 1 hour and then bound to magnetic nickel agarose 
beads.  The elution supernatants (eluted by 250 mM Imidazole) were analyzed by 
western blot for Hsp70 bound to tau.  The anti-Hsp70 western shows that Hsp70 
bound to the beads independent of tau (see last four lanes without tau).  In addition, 
Hsp70 seemed to bind better to the beads at 37 oC than 25 oC, indicating future 










Figure A.5 Isothermal titration calorimetry (ITC) of Hsp70 and 2N4R tau to 
determine binding constants. (from 5-24-10)  Hsp70 and 2N4R tau were dialyzed 
with three buffer changes (45 minutes at room temp., 1 hour at room temp., and 
overnight at 4 oC) in 100 mM NaCl, 10 mM Hepes pH 7.64, 0.1 mM EDTA, and 1% 
β-mercaptoethanol.  Protein was aliquoted into single use (5 ml tau at 9.3 µM and 500 
µl Hsp70 at 147.64 µM).  Using a MicroCal VP-ITC, the jacket temperature was set 
to 37 oC, tau was loaded into the cell, and Hsp70 was loaded into the syringe.  The 
following are the settings for injections: 30 injections (2 µl initial and 10 µl rest), 
reference power 10 µcal/sec, 310 rpm stirring speed.  The raw data (top image, black 
line) shows a consistent baseline (top image, red line), however, increasing heats with 
each injection.  The processed data (bottom image, black squares) which accounts for 
the baseline shows that as Hsp70 is injected into the cell containing tau, more heat is 
given off each injection.  This is the opposite of what should happen if two proteins 
bind to each other, as the injected protein will eventually bind all the protein in the 










Figure A.6 ITC of Hsp70 injection into buffer. (from 5-25-10)  Hsp70 at 147.64 
µM was injected into buffer at 37 oC using the same parameters as Figure A.5.  The 
raw data (top image, black line) shows that as more Hsp70 is injected into the cell the 
heat given off does not change, however the baseline (top image, red line) drifts 
significantly.  A normal dilution of injectant into buffer should have a flat baseline. 
The processed data (bottom image, black squares) shows a slight increase in the heat 










Figure A.7 ITC was run using an automated version of the VP-ITC. (from 8-12-
10) Data shown is of Hsp70 (147.64 µM) and 2N4R tau (10.372 µM) at the settings 
used in Fig A.5 and A.6, however the system automates everything from cleaning to 
injecting.  The raw data (top image, black line) indicates a decreasing amount of heat 
as more Hsp70 is added to the system and a steady baseline (top image, red line).  
The processed data (bottom image, black squares) shows that saturation was reached 
very soon in the experiment and lower concentrations of protein would shift the curve 










Figure A.8 ITC of Hsp70 and 2N4R tau shows results are difficult to reproduce. 
(from 8-18-10) Hsp70 (125 µM (black) and 147.64 µM (green) with 2N4R tau 
(10.372 µM) was run at 37 oC, 5 µl injections, 56 injections.  The raw data (top image, 
black and green lines) did not show reproduce results to those from Fig A.7.  We also 
saw a drifting baseline (top image, red lines).  The processed data (bottom image 
green and black squares) shows an almost random scatter of points.  These data 







Figure A.9 Surface plasmon resonance (SPR) using the BIAcore.  A CM-5 chip, 
used for immobilizing primary amines of the immobilized protein, was used to 
examine the binding of Hsp70 and tau.  Flowcell (Fc) 1 is a control channel that was 
activated and blocked with ethanolamine.  Fc2 contains immobilized Hsp70 (no his 
tag) recombinantly purified in our lab.  Fc3 contains immobilized commercially 
purified and purchased Hsp70.  Fc4 contains immobilized Tau12 antibody.  SPR is a 
phenomenon where changes in the refractive index of an immobilized protein in 
contact with a sensor chip are detected.  Upon binding of analyte to the immobilized 
protein, a change in the angle of reflection occurs and is measured by a sensor as a 
response unit (RU) over time (sec).  2N4R tau at 10 μM (analyte) was flowed over all 
four flow cells individually.  The highest response was from Fc1 which contains 
nothing, the second highest was from Fc4 with contains immobilized Tau12 antibody, 
and equal responses occurred from Fc2 and Fc3 which have Hsp70 immobilized.  






Figure A.10 A substrate binding domain (SBD) peptide for Hsp70 binds to 
Hsp70, but not to Tau12 antibody or the reference channel.  A peptide shown to 
have a high affinity for the substrate binding domain of DnaK (247) the E. coli 
homologue of Hsp70, was used to determine whether the binding of tau to Fc1 was 
something that would occur for every protein we might use to test the interaction of 
Hsp70 and tau.  The 11-mer peptide (VDKLY-(D-cyclohexylalanine)-LPRPT) was 
flowed over all four Fc at a concentration of 10 µM.  Only responses from Fc2 and 
Fc3, which contain immobilized Hsp70, were detected.  This indicates that tau 
binding to the reference channel is not a general phenomenon and perhaps we should 
use tau peptides in future experiments. Lines on the graph from top to bottom, Fc2, 







Figure A.11 2N4R tau and Hsp70 kinetic analysis. Despite having issues with tau 
binding in the reference channel we proceeded to determine if we could get any 
numbers for binding that correlate to previous data for tau and Hsc70 (186).  Tau 
(ligand at 0.5 µM) was captured by immobilized Tau12 antibody in Fc4, and Hsp70 
(analyte at 0-1000 nM) was flowed over with regeneration by 10 mM glycine at pH 
1.5.  Data for 0 nM Hsp70 was subtracted from (25 nM-1000 nM) and fit to a drifting 
baseline model.  The data had a Chi2 fit of 3.01, which is within the range of good fit, 
and a KD of 1.6 µM which is consistent with previous results for Hsc70 and 2N4R tau 






Figure A.12 SPR of 3R tau.  We proceeded to test whether 3R tau (2N3R) had a 
similar affinity for Hsp70 as 2N4R tau.  Shown is the compiled data of 2N3R flowed 
directly over Fc2 to examine direct binding to Hsp70.  Binding of 2N4R tau to Fc2 
was similar to Fig A.11 and was not repeated.  Shown in Fig A.12 is the aggregation 
of three separate trials of 2N3R tau (at 50, 250, 500 and 1000 nM (with 0 nM 
subtracted)) fit to a drifting baseline model.  The Chi2 value is 0.757, and the KD is 
0.182 µM.  This KD is the same as 2N4R tau; however, in examining the maximum 
response, 2N4R tau was at 148 RU while 2N3R was at 15.3 RU, indicating that even 
though Hsp70 and tau interact at similar affinities, there are almost 10x less binding 






Figure A.13 A deletion mutant of 4R tau for the predicted Hsp70 binding sites 
shows reduced affinity and overall binding.  A deletion mutant of residues I277, 
I278, I308, and V309 on 2N4R tau was analyzed by SPR for binding to Hsp70.  The 
aggregation of three trials is shown, similar to Fig A.12.  The Chi2 value is 2.65, the 
KD is 0.213 µM and the maximum response is 30.5 RU.  Compared to wild-type 
2N4R tau, there is a slightly reduced affinity, and a dramatically reduced (5x) amount 
of binding of Hsp70 and tau.  This indicates that the two hexapeptide regions flanking 






WT 2N4R WT 2N3R
ka (1/Ms) kd (1/s) KD (M) Chi2 ka (1/Ms) kd (1/s) KD (M) Chi2
11/22/2010 7.24E+03 1.26E-03 1.73E-07 3.29 Trial 1 (12-22-10) 1.23E+05 1.17E-02 9.51E-08 0.10
12/6/2010 6.84E+04 9.43E-03 1.38E-07 3.78 Trial 2 (1-4-11) 3.20E+04 1.09E-02 3.40E-07 0.43
12/15/2010 1.55E+04 2.49E-03 1.60E-07 3.01 Trial 3 (1-4-11) 6.53E+04 1.05E-02 1.61E-07 0.35
12/22/2010 3.54E+04 3.89E-03 1.10E-07 1.01 average 7.34E+04 1.10E-02 1.99E-07 0.29
average 3.16E+04 4.27E-03 1.45E-07 2.77 stdev 4.60E+04 6.11E-04 1.27E-07 0.17
stdev 2.72E+04 3.61E-03 2.76E-08 1.22 % SD of avg 62.70 5.54 63.78 59.34
% SD of avg 86.02 84.49 18.99 43.91
all at once 5.84E+04 1.06E-02 1.82E-07 0.76
Δ 278,279,308,309 2N4R
ka (1/Ms) kd (1/s) KD (M) Chi2
Trial 1 (12-22-10) 5.84E+04 1.22E-02 2.08E-07 0.43
Trial 2 (1-4-11) 5.03E+04 1.21E-02 2.40E-07 2.11
Trial 3 (1-4-11) 5.26E+04 9.20E-03 1.75E-07 0.61
average 5.38E+04 1.12E-02 2.08E-07 1.05
stdev 4.17E+03 1.70E-03 3.25E-08 0.92
% SD of avg 7.76 15.26 15.65 88.16
all at once 5.55E+04 1.18E-02 2.13E-07 2.65  
Table A.1 Analysis of binding of Hsp70 to various tau constructs.  Data from 
individual fits (black outline) was averaged together for wild-type 2N4R, wild-type 
2N3R, and Δ277, 278,308,309 2N4R.  Also, wild-type 2N3R, and Δ277, 278,308,309 
2N4R had all three trials fit at once, with similar outputs to individual fits.  The data 
shows the affinity of Hsp70 to the various tau constructs is similar, however as is 
shown in Fig A.11-13, the overall binding of Hsp70 and tau is less with 3R and 
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